**Microbiota effects and predictors of *Lactobacillus crispatu*s colonization after treatment with a**

**vaginal live biotherapeutic: results from a randomized, double-blinded, placebo-controlled trial**

**Authors & affiliations**

Seth M. Bloom*[1,2,3], Laura Symul*[4], Joseph Elsherbini[1], Jiawu Xu[1], Salina Hussain[1], Johnathan Shih[1],

Ashley Sango[1], Caroline M. Mitchell[1,3,5,6], Anke Hemmerling[7], Thomas P. Parks[8], Aditi Kannan[1], Fatima

A. Hussain[1,3], Craig R. Cohen[7], Susan P. Holmes[9], Douglas S. Kwon[1,2,3]

1. Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, Massachusetts, USA

2. Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA

3. Harvard Medical School, Boston, Massachusetts, USA

4. Institute of Statistics, Biostatistics and Actuarial Sciences (ISBA), Louvain Institute of Data

Analysis and Modelling (LIDAM), UCLouvain, Belgium

5. Department of Obstetrics & Gynecology, Massachusetts General Hospital, Boston,

Massachusetts, USA

6. Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston,

Massachusetts, USA

7. Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California San

Francisco, San Francisco, California, USA

8. Osel, Inc., Mountain View, California, USA

9. Department of Statistics, Stanford University, Palo Alto, California, USA

*Contributed equally

Correspondence: Douglas S. Kwon, dkwon@mgh.harvard.edu

**Abstract**

Bacterial vaginosis (BV) affects >25% of women worldwide and often recurs following treatment with the

standard-of-care antibiotic metronidazole (MTZ). Treatment with LACTIN-V, a live biotherapeutic product

(LBP) containing the *Lactobacillus crispatus* strain CTV-05, reduced recurrent BV (rBV) in a Phase 2b

clinical trial, but efficacy was incomplete. We analyzed trial samples to characterize microbiota and

immune effects and identify correlates of treatment success. By week 12, an *L. crispatus*-dominant

microbiota was achieved in 30% of LBP recipients compared to 9% of those in the placebo group (benefit

ratio: 3.31; p < 0.005). Most of this effect was due to CTV-05 colonization, although native *L. crispatus*

strains were also present and increased over time. Inflammatory cytokines decreased in both arms after

MTZ, but returned to baseline in the placebo group. Successful *L. crispatus* colonization was associated

with pre-MTZ microbiota composition, baseline inflammatory cytokine profiles, post-MTZ total bacterial

load, and selected clinical and behavioral variables. These findings elucidate LBP effects on vaginal

microbiota and identify predictors of treatment success, informing strategies to develop more effective

interventions to improve womens health.

**Introduction**

Bacterial vaginosis (BV), a vaginal syndrome characterized by *Lactobacillus*-deficient vaginal microbiota, affects 23-29% of women of reproductive age globally, with an estimated annual economic burden of $4.8 billion worldwide[1,2]. BV symptoms include vaginal discharge, malodor, pain, and itching, leading to significant impairments in quality of life, self-esteem, and sexual function[3,4]. In addition, BV is linked to mucosal inflammation and increased risk for numerous adverse health outcomes, such as HIV acquisition, sexually transmitted infections, preterm birth, human papillomavirus (HPV) infection, and cervical cancer[5–10]. While BV occurs globally, it disproportionately affects those with lower socioeconomic status and members of racial or ethnic minority groups across diverse settings[1,11–13]. Development of effective BV treatments is therefore a key objective to improve women's health worldwide[14].

Current first-line therapy for BV consists of oral or intra-vaginal antibiotics such as metronidazole (MTZ), which target many species within the diverse anaerobic bacterial communities characteristic of BV[2,14]. In most cases, MTZ reduces abundance of BV-associated anaerobes and leads to emergence of bacterial communities dominated by *Lactobacillus* species (which are intrinsically MTZ-resistant)[15], but BV frequently recurs after treatment. An Australian study of women with symptomatic BV found that 58% experienced recurrent BV (rBV) within 1 year of MTZ therapy, while a US trial that enrolled women with symptomatic BV and a prior history of post-treatment recurrence found that >75-80% experienced rBV within 16 weeks of treatment[16,17]. It is hypothesized that the incomplete efficacy of MTZ often results from a failure to eradicate BV-associated bacterial communities and/or from their post-MTZ replacement with *Lactobacillus* species prone to reverting to BV[15]. Studies have shown that *Lactobacillus iners* is associated with an increased risk of transition to BV-like states[18–20] and with higher rates of adverse health outcomes[6,21–24]. MTZ treatment frequently results in establishment of vaginal microbiota dominated by *L. iners* rather than *L. crispatus*[25–30], supporting the hypothesis that BV therapies which preferentially promote *L. crispatus* over *L. iners* may improve treatment outcomes and promote vaginal health[15,31,32].

New strategies to enhance *L. crispatus* colonization during BV treatment are in various stages of

development, including vaginal microbiome transplants, adjunctive therapies that selectively inhibit *L.

iners* and/or promote *L. crispatus* growth, and *L. crispatus*-containing live biotherapeutic products

(LBPs)[31–38]. The most advanced LBP in development is LACTIN-V, a vaginally-administered LBP

containing the *L. crispatus* strain CTV-05, and the only LBP tested in large-scale clinical trials[36,39]. Cohen

and colleagues recently reported results of a phase 2b multi-center, randomized, placebo-controlled,

double-blinded study showing that participants who received 11 weeks of intravaginal LACTIN-V after a

5-day course of intravaginal MTZ developed rBV at lower rates than placebo recipients[36]. Benefits from

LACTIN-V were observed at both week 12 (approximately 1 week after completing therapy; relative risk

of rBV = 0.66) and week 24 (approximately 13 weeks after completing therapy; relative risk of rBV =

0.73). However, rBV rates remained high even in the LBP arm, with 30% of recipients experiencing rBV

by week 12 and 39% experiencing recurrence by week 24 in the intention-to-treat analysis. In prior

reports, rBV was characterized using clinical measures, but comprehensive molecular analysis of vaginal

microbiota composition and factors associated with colonization were not assessed.

Here we characterize the effects of LACTIN-V on vaginal microbiota composition and identify correlates

of successful colonization by analyzing vaginal microbiota composition, bacterial strain dynamics,

cytokine profiles, and demographic/behavioral parameters of LACTIN-V phase 2b trial participants[36]. We

find that the reduction in rBV among LBP recipients corresponded to >3-fold higher rates of *L. crispatus*-

dominant colonization, but only 30% of recipients achieved *L. crispatus*-dominant vaginal microbiota at

week 12, consistent with the observed incomplete clinical efficacy. Microbiota trajectory and strain

dynamics revealed CTV-05 accounted for the majority of *L. crispatus* colonization among LBP recipients,

though endogenous strains increased over time and sometimes displaced CTV-05. We further describe

the effects of LBP treatment and microbiota composition on vaginal immune markers, and show that pre-

MTZ microbiota composition, baseline inflammatory cytokine profiles, post-MTZ total bacterial load, and

selected clinical/behavioral variables are associated with LBP treatment success. These results show

how an *L. crispatus* LBP alters vaginal microbiota composition to improve BV treatment efficacy while

identifying factors linked to LBP success that can guide development of future therapies to promote more

optimal vaginal microbiota communities and improved women's health outcomes.

**Results**

**Study design and participant characteristics**

Women aged 18 to 45 years with BV completed five days of standard intravaginal MTZ therapy and were

then randomized 2:1 to receive intravaginal LACTIN-V (Osel, Inc.) or placebo as previously described[36].

Enrollment occurred at four U.S. sites. LACTIN-V is a powder formulation containing the live *L. crispatus*

strain CTV-05, administered via prefilled, single-use vaginal applicators at a dose of $2\times10^9$ colony-forming

units (CFU). The placebo contained the same inactive ingredients without bacteria and was visually

indistinguishable. BV diagnosed at the baseline "pre-MTZ" screening visit required at least three of four

Amsel criteria and a Nugent score of $\geq4$[40,41]. Participants received five days of intravaginal MTZ gel within

30 days of diagnosis, and then were seen at a "post-MTZ" visit within 48 hours of completing antibiotics

for randomization to LBP or placebo. The first treatment dose was clinician-administered at the post-MTZ

visit, then participants self-administered doses daily for four consecutive days, followed by twice weekly

dosing for 10 weeks (ending at week 11 post-randomization; **Figure 1A**). Clinician-collected vaginal

swabs were obtained at the pre-MTZ and post-MTZ visits prior to randomization, and at weeks 4, 8, 12,

and 24 post-randomization. Detailed demographic, clinical, and behavioral data showed no notable

differences between arms[36]. The trial enrolled and randomized 228 participants (152 in the LBP arm and

76 in the placebo arm); samples from 213 of these participants (142 in the LBP arm and 71 in the placebo

arm) were available for this analysis, representing a total of 1,156 unique study visits.

**LBP Effects on *L. crispatus* and total *Lactobacillus* colonization**

Bacterial microbiota composition was determined by bacterial 16S V4 ribosomal RNA (rRNA) gene sequencing. Four samples were excluded due to technical failures of PCR amplification and sequencing ($<10^3$ processed reads per sample). Of the remaining 1,152 samples (**Table S1, Figure S1A**), the median number of analyzable reads per sample was 31,177 (IQR 23,774-41,251). No significant differences in microbiota composition were observed between study arms at either the pre-MTZ or post-MTZ visits (PERMANOVA *p* = 0.63 and *p* = 0.14, respectively; **Figure S1B-C, SI**).

To assess microbiota impacts of LBP treatment, we defined two outcome parameters based on microbiota proportional composition: ≥50% relative abundance of *L. crispatus* ("*L. crispatus*-dominant") and ≥50% summed relative abundance of *Lactobacillus* genus ("*Lactobacillus*-dominant", including *L. crispatus*). The primary microbiota endpoint for this analysis was establishment of an *L. crispatus*-dominant vaginal community at week 12, the timepoint corresponding to the trial's primary clinical endpoint[36]. Secondary microbiota endpoints were *L. crispatus*-dominance at week 24 and total *Lactobacillus*-dominance at weeks 12 or 24. Almost all participants in both treatment and placebo arms had non-*Lactobacillus*-dominant microbiota (<50% *Lactobacillus*) at the pre-MTZ screening visit, consistent with the fact that all had met criteria for clinical BV (**Figure 1B**). The majority in both arms transitioned to *Lactobacillus*-dominance at the post-MTZ visit that was largely driven by high relative abundance of *L. iners* (**Table S2**). Only one participant in each arm exhibited *L. crispatus*-dominant colonization at the post-MTZ visit (**Figure 1B**). Microbiota composition of the two arms diverged after randomization, with 30% of LBP recipients (n=37) compared to only 9% of placebo recipients (n=5) achieving *L. crispatus*-dominant colonization at week 12 (the primary endpoint), resulting in a benefit ratio of 3.4 (95% CI: 1.4 - 8.1; p < 0.005; **Table 1**, **Figure 1B-C**). At week 24, 35% of LBP recipients (n=39) versus just 8% of placebo recipients (n=4)  achieved *L. crispatus*-dominant colonization, for a benefit

ratio of 4.5 (95% CI: 1.7 - 11.9). The LBP did not increase rates of total *Lactobacillus*-dominant

colonization at week 12 compared to placebo (56% and 48% of LBP and placebo recipients, respectively;

benefit ratio: 1.16; 95% CI: 0.85 - 1.59), but did at week 24 (58% and 33% of LBP and placebo recipients,

respectively; benefit ratio: 1.76; 95% CI: 1.15 - 2.68; **Table 1**, **Figure 1B-C**).

We next investigated how these microbiota parameters related to the clinical diagnosis of BV by

comparing clinical and microbiota results for all post-randomization visits (weeks 4 and beyond, n = 729

visits). Among the 209 visits in which participants had ≥50% *L. crispatus* colonization, none had

concurrent clinical BV (**Table S3** and **Figure 1C**), and among 194 visits with <50% *L. crispatus* but ≥50%

total *Lactobacillus*, only 1% (n=2) had BV. However, of the 326 visits with <50% total *Lactobacillus*, 50%

(n=164) had clinical BV (**Table S3**). Thus, *Lactobacillus*-dominance (including *L. crispatus*-dominance)

was highly specific for the absence of BV, while non-*Lactobacillus*-dominance was highly sensitive but

less specific for BV.

In addition to sequencing-based microbiota composition analysis, total bacterial load in vaginal swab

samples was assessed via quantitative PCR (qPCR) at the post-MTZ and post-randomization visits.

Median bacterial load was significantly lower and more variable at the post-MTZ visit (median $10^{2.69}$

copies/swab; IQR $10^{0.08}$ - $10^{6.44}$) than at subsequent visits (median $10^{7.52}$ copies/swab; IQR $10^{7.09}$ - $10^{7.93}$

for all subsequent visits), consistent with antibiotic-mediated depletion of vaginal microbiota biomass

during BV treatment, followed by bacterial repopulation of the vaginal environment (**Figure 1D**). We

assessed whether post-MTZ microbiota composition (as determined by 16S rRNA gene sequencing) was

correlated with total bacterial load using a multi-table multivariate generalization of the squared Pearson

correlation, the RV coefficient[42,43]. This analysis revealed no significant correlation between post-MTZ

microbiota composition and bacterial load (RV coefficient = 0.02, *p*-value > 0.1).

**Microbiota composition trajectories throughout the trial**

To characterize microbiota trajectories with greater resolution, we summarized microbiota composition using topic mixtures[44,45]. Compared to clustering or categorizing samples into community state types (CSTs)[46], cervicotypes (CTs)[6], or sub-CSTs[47], this method provides probabilistic (rather than binary) weightings, allowing for more accurate descriptions of sample taxonomic composition and improved characterization of longitudinal dynamics[45]. In our cohort, assignment to reference CST performed poorly (median Bray-Curtis dissimilarity with assigned CSTs > 0.33, **SI**), especially for *Prevotella*-dominated samples (median BC dissimilarity > 0.5, **SI**), and with over 40% of samples being equally similar to two or more CSTs (**SI**). To identify topics, which can be interpreted as bacterial subcommunities (*i.e.,* consortia of bacterial taxa that co-occur with each other or with other taxa), and estimate their proportions in each sample, we fitted a latent Dirichlet allocation (LDA) model (a Bayesian "topic model")[48] to the taxonomic counts. We adapted a previously described approach[45] in which topics were constrained to be fully composed of either *Lactobacillus* or non-*Lactobacillus* species. Four non-*Lactobacillus* topics were inferred from the data (**Figure S2A, B**) and we defined four *Lactobacillus*-dominated topics, including three exclusively composed of a single *Lactobacillus* species (*L. crispatus*, *L. iners*, and *L. jensenii/mulieris*) and one composed of a mixture of the remaining *Lactobacillus* species (**Figure S2C**). **Figure 2A** shows inferred composition of each non-*Lactobacillus* topic, while **Figure 2B** displays topic proportions for each participant throughout the trial.

Three non-*Lactobacillus* topics were highly prevalent and abundant in both arms at the pre-MTZ visit, including topics in which the predominant taxa were *Candidatus* Lachnocurva vaginae (BVAB1), *Gardnerella swidsinskii/leopoldii*, and *Prevotella amnii* (**Figure 2C** and **S2D**). Microbiota composition shifted substantially at the post-MTZ visit (**Figure 2D**), where besides high *L. iners* relative abundance, the non-*Lactobacillus* topic with the highest relative abundance was the topic in which *Gardnerella swindsinskii/leopoldii* was predominant (**Figure 2C** and **S2D**). Another major shift in microbiota composition occurred between the post-MTZ visit and the week 4 visit, which was larger in the LBP arm

(median pairwise Bray-Curtis dissimilarity: 0.81; IQR: 0.50 - 0.97) than the placebo arm (median Bray-

Curtis dissimilarity: 0.58; IQR 0.41 - 0.80), driven primarily by increased *L. crispatus* abundance among

LBP recipients (**Figure 2C-D** and **S2D**). Microbiota composition was more stable after week 4, with

median Bray-Curtis dissimilarity <0.55 at week 8 and all subsequent visits, which was comparable

between arms (**Figure 2D**). LBP recipients who achieved *L. crispatus*-dominant colonization had more

stable microbiota than their counterparts (**Figure S2E, SI**).

The observation that microbiota composition became more stable after week 4 was also supported by

longitudinal patterns in microbiota categories. Among 115 participants with available data from both week

4 and week 12 visits, 71% (25 of 35; 95% CI: 53%-85%) of LBP recipients who achieved ≥50% *L.*

*crispatus* at week 12 also had *L. crispatus*-dominance at week 4 (**Figure 2B, Table S4**). Similarly, 71%

(27 of 38; 95% CI: 54%-84%) of LBP recipients who achieved *L. crispatus*-dominance at week 24 also

had *L. crispatus*-dominance at week 4 (**Figure 2B**, **Table S5**). However, early *L. crispatus*-dominant

colonization did not guarantee persistence, as only 49% (25 of 51) and 57% (27 of 47) of LBP recipients

with *L. crispatus*-dominance at week 4 retained it at weeks 12 and 24, respectively. By contrast, among

38 LBP recipients with non-*Lactobacillus*-dominant microbiota at week 4, 79% remained non-

*Lactobacillus* dominant at week 12 compared to just 10.5% each with *L. crispatus*-dominance or other

*Lactobacillus*-dominant colonization (**Table S4**). Thus, microbiota communities established early tended

to persist and early *Lactobacillus*-dominance – particularly *L. crispatus*-dominance – was strongly linked

to ongoing *Lactobacillus*-dominance.

**Metagenomic identification of the CTV-05 strain and assessment of *L. crispatus* strain dynamics**

The observation that LBP treatment promoted *L. crispatus* colonization prompted us to examine what

fraction of *L. crispatus* observed in LBP recipients represented the CTV-05 strain versus non-LBP native

strains. We used metagenomic sequencing to assess *L. crispatus* strain dynamics, with strain genotypes

and proportions inferred using StrainFacts[49]. In a separate analysis, simulations and experimental spike-

in data showed that StrainFacts performs well at inferring LBP (including CTV-05) strain genotypes and

proportions in samples with ≥5% overall relative abundance of *L. crispatus*[50]. In the LACTIN-V trial

samples, *L. crispatus* strain inference was successful in 313 samples, identifying 24 genotypically distinct

strains with at least 10% fractional strain abundance in at least one sample. To determine which strain

represented CTV-05, we generated a closed assembly of the CTV-05 genome, which nearly perfectly

matched the StrainFacts genotype of a widely prevalent inferred strain within the metagenomic dataset

(Jaccard similarity >0.999). Among 57 samples with inferred *L. crispatus* strain composition from placebo

recipients (any visit) or from LBP recipients prior to LBP administration, StrainFacts inferred CTV-05

presence in just 5 total samples from 5 unique participants (**Figure 3A**). This result suggested our strain

inference approach had a low false positive CTV-05 detection rate; we cannot rule out that some "false

positives" represented native strains with high genotypic similarity to CTV-05. Collectively, these results

support that CTV-05 detection was achieved with high accuracy in sample metagenomes.

To further characterize fidelity of the strain-tracing approach, we analyzed inference results for native *L.*

*crispatus* strains, supplemented by targeted bacterial isolations and genome sequencing to

experimentally test bioinformatic predictions. Most participants in whom a native strain was inferred

exhibited colonization by only a single native strain at any point during the study, with a few participants

colonized by two or three native strains (**Figure 3B**). Since StrainFacts inferences are performed blinded

to whether samples are derived from the same participant[49,50], consistent detection of the same 1-3 native

strains in multiple samples from the same participant additionally supported validity of the inferences. We

also performed targeted bacterial isolations of *L. crispatus* from a subset of samples inferred to contain

CTV-05, one or more native strains, or a mixture of CTV-05 and native strains. The resulting isolates

were highly genotypically similar to inferred strains from the same samples, including both CTV-05 and

native strains (results for an example participant shown in **Figure 3C-E**, with additional participants

detailed in **Figure S3A**). These experimental results further validated our metagenomic strain inference

approach.

We examined *L. crispatus* strain dynamics by classifying samples with inferred strain data into three

categories: samples with >90% CTV-05 fractional strain abundance ("High-CTV-05"), samples with 10-

90% CTV-05 ("Mixed"), and samples with <10% CTV-05 ("Low-CTV-05"; **Figure 3A**). These thresholds

were defined based on simulations to determine parameters maximizing reliability of strain detection[50].

At each post-randomization timepoint, the majority of LBP recipients with analyzable *L. crispatus* strains

had high-CTV-05 strain abundance, but the proportion with high-CTV-05 or mixed strains decreased over

time, while the proportion with high native *L. crispatus* strain abundance (*i.e.*, low-CTV-05) increased

(**Figure 3A**). At week 4, 96.1% (n=74) of LBP recipients with ≥5% *L. crispatus* had high-CTV-05 or mixed

strains, while just 3.9% (n=3) had high native strains. However, by week 24 only 63.2% (n=31) had high-

CTV-05 or mixed strains while those with high native strains increased to 36.8% (n=18). To characterize

this phenomenon in greater detail, we examined CTV-05 fractional strain abundance for each pair of

consecutive post-randomization visits (**Figure 3F-G**). Among 144 visits with high-CTV-05, two main

outcomes were observed at the next visit: 68% (n=98) maintained high-CTV-05 and 26% (n=38)

transitioned to <5% total *L. crispatus* colonization (strain composition undetermined). Among the 18 visits

with high native strain abundance, 61% (n=11) retained high native strain abundance at the next visit and

none transitioned to CTV-05 dominance. Interestingly, among 23 visits with mixed CTV-05/native strain

composition, only one (4%) transitioned to high-CTV-05, while 39% (n=9) remained mixed and 35% (n=8)

transitioned to high native strain abundance, including some transitions to high native strain abundance

that occurred while participants were still receiving LACTIN-V (**Figure S3B**). These results show CTV-05

was frequently the sole or dominant *L. crispatus* strain in LBP recipients, but when native strains

dominated or co-occurred with CTV-05, they often replaced CTV-05 at subsequent visits but were almost

never replaced by it.

**Intervention effects on vaginal inflammation**

We assessed the effects of MTZ and LBP treatment on vaginal mucosal immune state and inflammation by measuring cytokine and chemokine concentrations in vaginal swab eluates using a previously described custom Luminex assay[6,45]. Concentrations of 18 cytokines and chemokines were log-transformed for variance stabilization and imputed when outside their respective limits of quantification (**Figure S4A**). Concentrations of all chemokines and cytokines were strongly correlated, with the first principal component (PC1) accounting for 50% of the total variation (**Figure S4B**). This phenomenon suggested a size-effect[51] that we attributed to the (unmeasured) variation in biomass collection between swabs, which was addressed through PC1-subtraction (**SI**). Seven cytokines were excluded from analysis because a large proportion of values were outside the quantification range (**Figure S4A**). Mucosal immune dynamics during treatment were determined by comparing adjusted concentrations of each cytokine or chemokine from each participant's baseline (pre-MTZ) visit with concentrations at subsequent visits.

We first examined how chemokines and cytokines with known relationships to BV and vaginal microbiota composition[5,6,52,53] changed during treatment. IL-1β concentrations decreased post-MTZ in both arms, while IP-10 showed the opposite pattern, consistent with previously reported pattern with BV treatment[52] (**Figure 4A-B**). These effects persisted in both arms through week 12, but IL-1β and IP-10 returned to pre-MTZ levels by week 24 in placebo recipients, leading to a difference of -0.39 (95% CI: -0.66 – -0.14) between adjusted concentrations in the LBP versus placebo arm for IL-1β and of 0.51 (95% CI: 0.21 - 0.79) for IP-10. By contrast, IL-6 concentrations – which have been reported not to differ between women with and without BV[52] – remained unchanged from pre-MTZ levels in both treatment arms throughout the study (**Figure 4C**). Sensitivity analyses examining the data prior to adjustment for size-effect via PC1-subtraction revealed findings that were qualitatively similar, but with reduced magnitude (**SI**).

The reversion of treatment-induced effects for IL-1β and IP-10 concentrations in placebo recipients by

week 24 suggested an association with total *Lactobacillus* relative abundance, which differed between

treatment arms at this visit (**Table 1**). We therefore examined the correlation of microbiota composition

(summarized by topic proportions) with mucosal cytokine/chemokine concentrations. Their RV coefficient

was 0.18 with p-value <0.005 (permutation test), indicating significant correlation. Similar RV coefficient

values were obtained when repeating analysis independently for each visit (**Figure S4C**) except for a

substantially lower correlation at the post-MTZ visit (where microbiota absolute abundance varied widely,

**Figure 1D**), suggesting microbiota-immune correlation was not driven primarily by a participant effect.

To characterize the microbiota-immune relationship in greater detail, we employed DiSTATIS[54], a method

that uses between-sample dissimilarity matrices to infer a consensus matrix across two datasets and

associated latent components. Projecting microbiota topic relative abundances and transformed

cytokine/chemokine concentrations onto this latent subspace using correlation circles revealed that the

first latent dimension discriminated *Lactobacillus*-dominated samples from non-*Lactobacillus*-dominated

samples (**Figure 4D-F**). Chemokines MIG (CXCL9), IP-10 (CXCL10), and ITAC (CXCL11) had high

positive correlation along the first latent dimension, indicating positive covariation with *Lactobacillus*,

while IL-1β, TNF-α, and IL-1α had high negative correlations, indicating positive covariation with non-

*Lactobacillus* species (**Figure 4E**). The second latent dimension discriminated *L. crispatus* from *L. iners*

but most cytokines and chemokines had little or no correlation with that component, indicating minimal

association of inflammatory markers with individual *Lactobacillus* species (**Figure 4E**). Most cytokines

and chemokines had high correlations with the 3rd and/or 4th latent components but the microbiota topics

did not, indicating a degree of immune variation that was microbiota-independent (**Figure 4F**). In these

dimensions, IFNγ and IL-17 correlated with each other but were anti-correlated with IL-6, MIP-3α, MIP-

1β, and MIP-1α. Notably, although IP-10 levels were previously reported to differ in a small subset of

LACTIN-V recipients based on whether participants were highly colonized by CTV-05 versus non-CTV-

05 *L. crispatus* strains (as measured by qPCR)[56], we observed no clear differences in microbiota

correlation with cytokine/chemokine levels (including IP-10) in analysis that distinguished CTV-05 from

other *L. crispatus* strains (**Figure S4D-G**).

**Heterogeneity in LBP treatment effect based on baseline microbiota composition**

We next performed exploratory *post-hoc* analyses to investigate whether differences in pre-MTZ

microbiota composition corresponded to differences in response to the LBP (*i.e.,* heterogeneity of

treatment effect). We stratified participants by their most abundant pre-MTZ taxon (aggregated at the

genus-level), identifying four groups for analysis: *Lactobacillus*-predominant, *Gardnerella*-predominant,

*Prevotella*-predominant, and *Ca.* Lachnocurva vaginae (BVAB1)-predominant. LBP treatment benefit

was evaluated for each group with respect to two distinct outcomes: ≥50% *L. crispatus* colonization (at

week 12 or 24) and BV recurrence (by week 12 or 24) (**Figure 5A**). Heterogeneity in benefit among pre-

MTZ microbiota groups (**Figure 5B**) was tested using an analysis of deviance comparing nested logistic

regression models allowing (or not) for heterogeneity and adjusting for multiple testing by controlling for

the false discovery rate (Methods, **SI**).

Analysis of the relationship between pre-MTZ microbiota groups and establishment of *L. crispatus*-

dominant colonization suggested some groups benefitted more from LBP treatment than others (adjusted

*p*-values = 0.11 at week 12 and 0.03 at week 24; **Figure 5C, D**). LACTIN-V recipients with pre-MTZ

predominance of *Lactobacillus*, *Gardnerella*, or *Prevotella* attained higher rates of *L. crispatus*-dominant

microbiota at both weeks 12 and 24 compared to their placebo counterparts, with modestly larger rate

differences at week 24 (**Figure 5D**). In contrast, participants with pre-MTZ *Ca.* Lachnocurva vaginae

(BVAB1) did not differ in *L. crispatus*-dominant colonization between LBP and placebo arms. Analysis of

BV recurrence also showed differences in benefit from LBP treatment based on pre-MTZ microbiota

(adjusted *p*-values <0.05 at week 12 and <0.01 at week 2; **Figure 5E-F**). Among LBP recipients with pre-

MTZ *Prevotella*-predominance, BV recurred in almost all placebo recipients by week 24, compared to

just over half of LBP recipients. By contrast, LBP recipients whose most prevalent taxa pre-MTZ was Ca.

*Lachnocurva vaginae* (BVAB1) were unique in exhibiting slightly higher absolute rates of rBV than those

who received placebo (**Figure 5E-F**). We used similar methods to perform a sensitivity analysis in which

participants were grouped based on pre-MTZ CSTs[57] or using a model-based approach relying on topic

relative abundances. Findings from this analysis were largely consistent with results of our predominant-

taxon analysis above (**Figure S5, SI**). Together, these exploratory  analyses showed that benefits of LBP

treatment in achieving *L. crispatus*-dominance and preventing BV recurrence differed depending on pre-

MTZ microbiota composition, with participants who had pre-MTZ predominance of *Ca.* Lachnocurva

vaginae (BVAB1) exhibiting a lack of benefit compared to placebo, whereas other participants

experienced more favorable responses.

**Factors associated with achieving *L. crispatus* dominance in LBP recipients**

To identify factors associated with establishing *L. crispatus* dominance among LBP recipients, we

performed a series of multiblock partial least square discriminant analyses (MB-PLS-DA) on the

longitudinal LACTIN-V arm data (**Figure 6A-C**, **S6**, **S7A**). Based on the observation that early *L.*

*crispatus*-dominant colonization correlated with *L. crispatus* colonization at later visits (**Table S4**, **S5**), we

analyzed factors from prior visits that associated with the participants' microbiota category by week 4, as

well as separate analyses of factors associated with microbiota category at ensuing visits. We defined

three models corresponding to the different phases of the trial: the "initial phase" spanned from the post-

MTZ visit to week 4, the "continuation phase" spanned from week 4 to week 12, and the "follow-up phase"

spanned from week 12 to week 24 (**Figure S6A**). For each phase, factors of interest (*i.e.,* explanatory

variables) were grouped into 13 thematic blocks (**Figure 6A**, **Table S6**). The first block characterized

participant demographics, blocks 2-4 described participant baseline vaginal ecosystem (*i.e.*, pre-MTZ

microbiota composition and diversity, pH, cytokines concentrations), blocks 5-8 quantified the vaginal

ecosystem at the previous visit (*e.g.,* at the post-MTZ visit in the initial phase, when the response is week

4 colonization status), while blocks 9-13 characterized participant sexual behavior, douching/bleeding,

antibiotic use, and product adherence (**Table S6**). For each phase, MB-PLS-DA was used to evaluate

the ability of these variables to discriminate between the following microbiota categories at each visit

starting from week 4: ≥50% *L. crispatus*, ≥ 50% *Lactobacillus* but <50 % *L. crispatus*, or < 50%

*Lactobacillus* (see also **Figure 1B**). We also used nested models to assess the additional contribution of

specific blocks in discriminating colonization status (**SI**, **Figure S6A-C**).

In the model for the LBP arm initial phase, the most important block for discriminating week 4 colonization

categories was the previous (*i.e.,* post-MTZ) vaginal environment (**Figure 6A**, left panel). This block

included post-MTZ total bacterial load, α-diversity, and pH. Lower values of these three factors were

associated with higher chances of ≥50% *L. crispatus* at week 4, and were among the 5 most important

variables in the model (**Figure 6B-C** and **S7A**). The next most important blocks were demographics and

blocks characterizing participant pre-MTZ vaginal environment, including pre-MTZ vaginal pH, α-

diversity, cytokine concentrations, and microbiota composition (as described by topic proportions, **Figure**

**6A** and **S7A**). Specifically, high pre-MTZ α-diversity and pH were negatively associated with *L. crispatus*

colonization at week 4 (**Figure 6B**). Interestingly, pre-MTZ adjusted concentrations of the chemokine IL-

1β were positively associated with achieving *L. crispatus*-dominance at week 4 while pre-MTZ IP-10 and

MIG levels showed an opposite association (**Figure 6B**, **6D**). Self-declared race and education were the

most important demographic block variables, with white and more highly educated participants having

higher rates of *L. crispatus*-dominance (**Figure S7A**). However, race and education were highly

correlated in the cohort (**Figure S7B**) such that their individual contributions to explaining *L. crispatus*

colonization could not be clearly distinguished. While these two demographic variables were also

correlated with several pre-MTZ vaginal characteristics that also explained colonization such as pre-MTZ

α-diversity (**Figure S7C**), they still mildly contributed to model explanatory power (**Figure S6C**). The

remaining blocks or variables were not important for discriminating between initial phase colonization

categories (**Figure 6A-B**, **Figure S7A**), possibly because variables in these blocks contributed limited

information as overall adherence was high, use of antibiotics and douching was relatively rare, and some

birth control options were rare in this cohort (**SI**). In contrast, within these blocks, factors with higher

heterogeneity across participants such as bleeding and sexual activity showed greater variable

importance (**Figure S7A**).

In the continuation phase model for the LBP arm (from week 4 to week 12), the colonization category at

the previous visit was by far the most important block associated with colonization category at the

following visit (**Figure 6A**), consistent with higher stability of microbiota composition from week 4 to 12

(**Figure 2D**). While no other blocks significantly improved model performance (**Figure S6C**), individual

variables including sexual activity, bleeding, douching, and non-hormonal IUDs were all negatively

associated with high-level *L. crispatus* colonization (**Figure S7A**). In the model for the LBP follow-up

phase (from week 12 to week 24), the colonization category at the previous visit (*i.e.,* week 12) was again

strongly associated with the colonization category at week 24. However, in contrast to the previous phase,

sexual behavior and antibiotic use only mildly contributed in explaining week 24 colonization categories

(**Figure 6A**, right panel, **Figure S6C**, **S7A**).

Analogous analyses for placebo recipients did not show significant predictive value for either the initial

phase or the follow-up phase in cross-validation (**Figure S8A-C**, **S9**). The placebo continuation phase

model had modest predictive value, with microbiota category at the previous visit serving as the best

predictor of microbiota category at the next visit (**Figure S8A-C**, **S9**).

**Discussion**

Treatment with vaginal live biotherapeutic products (LBPs) offers significant promise to improve health,

but mechanisms, correlates, and strain dynamics of LBP colonization and efficacy remain incompletely

understood[58]. We performed comprehensive analyses of samples and data from a randomized, double-

blind, placebo-controlled phase 2b trial of LACTIN-V, a single-strain *L. crispatus* LBP for prevention of

BV recurrence[36]. We employed microbiome sequencing, strain tracing, and immunologic characterization

together with multi-block analysis of biological, clinical, demographic, and behavioral parameters to investigate LBP effects and correlates of treatment success. LACTIN-V treatment resulted in *L. crispatus*-dominant vaginal bacterial communities in 30% and 35% of recipients at weeks 12 and 24, respectively, representing 3.4- and 4.5-fold higher rates than in placebo recipients. *L. crispatus* colonization among LBP recipients was substantially due to the LACTIN-V strain CTV-05, although dominance by native *L. crispatus* strains increased over time. Microbiota trajectory analysis showed that microbial communities established early frequently persisted. Achieving *Lactobacillus*-dominance – particularly *L. crispatus*-dominance – at early timepoints was strongly linked to persistence of *Lactobacillus*-dominance, while early non-*Lactobacillus*-dominance also tended to be maintained. In exploratory post-hoc analyses, we found that the LBP's benefits differed based on baseline vaginal microbiota composition, and we identified specific microbial, immune, demographic, and behavioral factors associated with high-level *L. crispatus* colonization among LBP recipients.

To enhance resolution and power, we relied, for most of our analyses, on the observed relative abundances of species, genera, or *de novo* topics rather than on *de novo* clusters or assignment to reference community state types (CSTs). This approach is based on prior work showing that diverse vaginal microbiotas do not exhibit well-defined clusters[59,60] which we also observed in this cohort. We also favored taxa-based reporting to facilitate interpretation and comparison with past or future studies, noting that CST definitions remain in flux as datasets expand beyond predominantly U.S. populations.

To elucidate mechanisms by which the LBP promoted *L. crispatus* colonization, we investigated *L. crispatus* strain dynamics using both metagenomic analysis and cultivation-based strain characterization. Metagenomic strain inferences showed the CTV-05 strain accounted for the majority of *L. crispatus* colonization among LBP recipients, but native *L. crispatus* strains were also observed. Interestingly, among LBP recipients with ascertainable *L. crispatus* strain composition, 96.1% had CTV-05 as their dominant or co-dominant strain at week 4, but this proportion progressively declined, while the number

of participants with dominance by one or more native *L. crispatus* strains rose from 3.9% at week 4 to

36.7% at week 24.  Recipients with CTV-05 strain dominance at a given visit tended to either maintain

CTV-05 dominance or exhibit substantial loss of *L. crispatus* at the ensuing visit. However, recipients with

co-dominance of CTV-05 and native strains frequently experienced replacement of CTV-05 by the native

strain at the next visit, but very rarely exhibited replacement of the native strain by CTV-05. Further

research is needed to determine whether native *L. crispatus* strains that outcompeted CTV-05 have

functional characteristics providing selective advantages and whether initial CTV-05 colonization

establishes a more permissive environment for eventual transition to native *L. crispatus* strains.

We also examined impacts of MTZ and LBP treatment on mucosal inflammation by measuring vaginal

cytokines and chemokines. Significant changes in several cytokines and chemokines were observed in

participants for whom treatment successfully shifted microbiota composition to *Lactobacillus*-dominance,

and these changes reverted in participants who shifted back to non-*Lactobacillus*-dominance. Most

notably, inflammatory cytokines including IL-1α, IL-1β, and TNFα increased as *Lactobacillus* abundance

decreased, whereas IP-10, MIG, and ITAC showed the opposite pattern, consistent with prior

reports[5,6,52,53]. These effects appeared primarily driven by genus-level *Lactobacillus* abundance rather

than a particular species. A prior study examining a subset of LACTIN-V trial participants in whom strain

abundance was assessed by qPCR reported that IP-10 levels were lower at week 24 in participants with

CTV-05 colonization than those colonized by other *L. crispatus* strains[56], but we did not observe a similar

association in our analysis of the full cohort. Treatment-induced cytokine changes persisted in the LBP

arm at week 24 compared to placebo, but this was driven primarily by the LBP's effect in promoting higher

rates of *Lactobacillus*-dominance rather than a strain-specific effect of CTV-05.

Our *post-hoc* analysis of treatment outcomes showed LACTIN-V's incomplete efficacy in achieving high-

level *L. crispatus* colonization and preventing BV recurrence was linked to differences in pre-MTZ

microbiota composition. Stratifying participants by their predominant bacterial genus at the pre-MTZ visit

revealed between-group differences in achieving *L. crispatus*-dominance at week 24 and in preventing

rBV by both weeks 12 and 24. Most prominently, these analyses showed a particular benefit from the

LBP in preventing BV recurrence among participants with pre-MTZ *Prevotella*-predominance, whereas

participants with pre-MTZ *Ca.* Lachnocurva vaginae (BVAB1)-predominance uniquely exhibited a trend

toward higher BV recurrence rates with LBP treatment and little or no benefit from the LBP in achieving

*L. crispatus*-dominance. The reasons for these patterns are unclear, but may reflect greater competitive

ability or MTZ resistance in *Ca.* Lachnocurva vaginae or its co-occurring species[61,62]. Since *Ca.*

Lachnocurva vaginae remains uncultured[63,64], experimentally testing its antimicrobial susceptibility and

ability to compete with other species is currently infeasible, but our results highlight its cultivation and

phenotypic characterization as key research priorities. However, we emphasize that these results

showing pre-MTZ microbiota effects on LBP efficacy are based on exploratory analyses of a relatively

small study cohort, which can introduce arm imbalances through *post-hoc* stratification. They should

therefore be regarded as hypothesis-generating observations that require replication and validation in

future studies.

We also performed integrated multiblock analysis of LBP recipients to identify biological, clinical,

demographic, and behavioral correlates of *L. crispatus*-dominant colonization and other microbiota

outcomes in LBP recipients. Low total bacterial load, low vaginal pH, and low microbiota α-diversity at

the post-MTZ visit were associated with *L. crispatus*-dominant colonization. Low pre-MTZ vaginal

concentrations of MIG and IP-10 and high concentrations of IL-1β were also associated with *L. crispatus*-

dominance at week 4 – an unexpected finding given their opposite correlations with *Lactobacillus*

abundance during concurrent visits. The explanation for this observation is unclear, but may involve a

more vigorous pre-MTZ mucosal immune response helping to clear BV-associated bacteria, presence of

inflammatory but MTZ- or LBP-responsive bacteria in some participants at baseline, or other

mechanisms. After week 4, the strongest predictor of a participants' microbiota category was their

microbiota category at the previous timepoint, indicating that microbiota composition established early

after LBP treatment best predicts subsequent outcomes. Demographic data including self-declared race

and education levels were also linked to microbiota composition at week 4 and beyond, but since race

and education were closely correlated and likely associated with unmeasured variables, this precluded

clear mechanistic interpretation. Despite evidence for sexual activity as a significant influence on BV and

vaginal microbiota composition[65], we did not identify a strong signal for sexual behavior as an explanatory

variable for microbiota composition in LBP recipients. This may be because of little variation in self-

reported sexual behavior throughout the trial such that effects of protected or unprotected sex may have

occurred early and been obscured by one of the many factors associated with early *L. crispatus*

colonization. It is also recognized that self-reported sexual activity in clinical trials may not be a reliable

measure of actual sexual activity[66–69], and reporting biases or inaccuracies can decrease power to detect

effects.

In summary, our detailed analysis of the vaginal microbiota effects of a single-strain *L. crispatus* LBP

reveals patterns of microbiota composition and strain dynamics underlying the clinical effects of LACTIN-

V. We identify key microbiota and host factors associated with treatment success and *L. crispatus*

colonization. If validated, these findings could help identify patients most likely to benefit from LBP

treatment and guide the discovery of novel therapeutic targets to enhance LBP efficacy and improve

women's health outcomes globally.

**Limitations**

This study has several limitations. First, samples from a few participants in the primary clinical trial were

not available for microbiome and cytokine analysis (samples were unavailable from 10 of 152 originally

reported participants in the LBP arm and 5 of 76 participants in the placebo arm). In addition, technical

failures of 16S rRNA gene sequencing precluded microbiota compositional analysis in four additional

samples, so our analysis cohort was slightly smaller than the primary trial cohort. Second, the limited size

of this Phase 2b study reduced statistical power, especially for heterogeneity and between-arm *L.*

*crispatus* colonization comparisons. Third, the study's relatively infrequent sampling schedule did not

permit high temporal resolution to assess microbiota and strain dynamics. Finally, although detailed data

were available regarding sexual, contraceptive, hygiene, and clinical parameters, participants were

surveyed on only a narrow range of environmental and sociodemographic variables, precluding detailed

investigation of factors that might help explain associations with microbiota composition.

**Methods**

**Study design and sample collection**

Samples analyzed in this study were obtained as part of a previously reported phase 2b, randomized,

double-blind, placebo-controlled trial of the *L. crispatus* LBP LACTIN-V (Osel, Inc., Mountain View, CA)

for prevention of rBV[36]. Use of samples was approved by the Mass General Brigham Institutional Review

Board (IRB Protocol #:2020P002237) as well as the UCSF Institutional Review Board (IRB Protocol#:

19-28337). LACTIN-V is a single-strain LBP formulated as a powder containing a preservation matrix and

$2 \times 10^9$ colony-forming units (CFU) per dose of the *L. crispatus* strain CTV-05, which was isolated from a

human vaginal sample[36]. CTV-05 is administered using a pre-filled vaginal applicator, and was compared

in the trial to a placebo formulation consisting of the preservation matrix without CTV-05. The trial was

conducted at four centers within the USA and enrolled premenopausal, non-pregnant women aged 18-

45 years. Eligibility criteria were previously described[36]. Briefly, potential participants attended a

screening (pre-MTZ) visit at which they were determined to be eligible for the study if testing revealed

presence of BV as determined by both a Nugent score of 4-10 on Gram stain of a vaginal smear[41] and

presence of at least three of four Amsel criteria (characteristic vaginal discharge, >20% clue cells on

microscopy of a vaginal wet prep, vaginal fluid pH >4.5, and presence of a fishy odor upon addition of

10% potassium hydroxide to a vaginal specimen)[40], as well as negative testing for HIV, syphilis,

gonorrhea, chlamydia, trichomonas, and urinary tract infection. Women found to be eligible based on this

evaluation completed 5 days of intravaginal MTZ therapy within 30 days of their pre-MTZ visit (**Figure**

**1A, S1A)**. They then returned to the trial clinic within 48 hours of completing antibiotics (post-MTZ visit)

and were randomized in a 2:1 ratio to receive either LBP or placebo after providing written informed

consent. The first dose of LBP or placebo was clinician-administered at the randomization (post-MTZ)

visit, then doses were vaginally self-delivered daily for the next four days, then twice weekly for ten

additional weeks. In-person study visits were scheduled 4, 8, 12, and 24 weeks after randomization, at

which vaginal swabs were collected and stored (details below) and clinical report forms (CRFs) were

completed. In addition, two phone visits were planned at week 16 and 20 during which a subset of the

clinical report forms were filled to capture information on adverse events, menstruation, concomitant

medication use, and sexual behavior protected or unprotected by condoms.  Participants who desired

additional in-person visits were invited to present to the clinics. Swabs and CRFs were collected at these

additional visits.

Clinician-collected vaginal swab samples were obtained via speculum exam at in-person study visits.

Two types of swabs were collected in parallel for analysis[36]. One set of swabs was  collected at all in-

person visits including the pre-MTZ (screening) visit using the Starplex™ Scientific Multitrans™

Collection and Transportation System (Starplex™ Scientific S1600), which comprises a plastic-shaft

Dacron™-tipped swab stored in a glass bead-containing transport medium consisting gelatin (5.0 g/L),

sucrose (68.46 g/L), glutamic acid (0.70 g/L), HEPES sodium salt (3.4 g/L), modified Hank's balanced

salts (9.8 g/L), sodium bicarbonate (0.35 g/L), bovine serum albumin (10 g/L) and the antimicrobial agents

vancomycin (0.1 g/L), amphotericin B (2.5 mg/L), and colistin (0.015 g/L) at a pH of 7.2-7.8. The other

set of swabs was collected at the post-MTZ (randomization) visit and all subsequent visits in the ESwab®

Liquid Based Collection and Transport System (Copan ESwab 480C®). Samples were stored at room

temperature for 1-4 hours after collection, then frozen at -80°C.

Microbiota sequencing, bacterial isolation, and cytokine analysis was performed on samples stored using

the Starplex™ system. Samples were thawed on ice, vortexed at maximum speed for 5 seconds, then

the swabs were removed from the transport media and media was divided into aliquots and re-frozen at

-80°C. Subsequent processing was performed as described below. Measurement of bacterial load via

qPCR was performed using swabs collected via the Copan ESwab® system.

**Bacterial isolations and cultivation**

Bacterial isolation and cultivation was performed under anaerobic conditions at 37°C in an AS-580

anaerobic chamber (Anaerobe Systems) with an atmosphere of 5% carbon dioxide, 5% hydrogen, and

90% nitrogen (Airgas, Inc.). All culture media was pre-reduced prior to use by being placed in the

anaerobic chamber overnight. Bacteria were isolated and cultivated on solid media including

*Lactobacillus* MRS agar (Hardy Diagnostics, #G117), Columbia Blood Agar ("CBA", Hardy Diagnostics,

#A16), or CDC Anaerobe Laked Sheep Blood Agar with Kanamycin and Vancomycin ("LKV", BD BBL™

Prepared Plated Media, #221846). Known *L. crispatus* strains and not-yet-identified isolates obtained on

*Lactobacillus* MRS agar were expanded by culture in liquid media consisting of *Lactobacillus* MRS broth

(BD #288130) prepared according to manufacturer instructions. Isolates obtained on CBA agar or LKV

agar were expanded in liquid media consisting of either Wilkins-Chalgren Anaerobe Broth (Thermo

Scientific™ Oxoid™, #CM0643B; prepared according to manufacturer instructions) or of NYCIII broth

(American Type Culture Collection (ATCC) medium 1685), whichever produced better growth. NYCIII

broth was prepared using a slightly modified version of the standard ATCC protocol[34]. Pre-media

consisted of 4 g/L HEPES (Fisher Scientific, #BP310-500), 15 g/L proteose peptone no. 3 (BD

Biosciences, #BD 211693), and 5 g/L sodium chloride in 875 ml distilled water, which was pH-adjusted

to 7.3 and autoclaved on liquid protocol at 121°C for 15 minutes, then cooled and stored at 4°C. One day

before use, complete NYCIII broth was prepared from the autoclaved, cooled pre-media by adding

dextrose (from a stock of 3 g per 45 ml; Fisher Chemical™, #D16-500) at 7.5% v/v, yeast extract solution

(Gibco, #18180-059) at 2.5% v/v, and heat-inactivated horse serum (Gibco, #26050070) at 10% v/v, then

sterilized by passage through a 0.22 µm vacuum filter.

To establish a genome sequence for the CTV-05 strain, a cryopreserved pure culture of CTV-05 was

obtained from Osel, Inc. The strain was streaked for isolation on *Lactobacillus* MRS agar and cultured

for 48 hours, then a single colony was picked into *Lactobacillus* MRS broth and incubated for 20 hours.

The broth culture was harvested by centrifugation to obtain bacterial pellets for genomic DNA extraction

and sequencing.

Bacterial isolations were performed from twelve selected trial samples (see **Figure 3C-E**, **S3A**) using a

modification of previously described methods[34]. Since samples had been collected into Starplex™

transport medium containing antibiotics (see above), the samples were thawed on ice, immediately

diluted into pre-reduced Dulbecco's Phosphate Buffered Saline ("PBS", Millipore Sigma, #D8537) at 1:12

v/v, centrifuged for 10 minutes at 10,000 rcf, then supernatant was removed. Pellets were re-suspended

in PBS and re-centrifuged with removal of supernatant two more times, then resuspended in PBS, diluted

in serial 10-fold dilutions, and 100 $\mu$l aliquots from each dilution were plated evenly on MRS, LKV, and

CBA agar in parallel. Plates were incubated for 7 days and multiple examples of each distinct colony

morphology from each sample were picked and subcultured onto solid media of the same type as the

source media, with an emphasis on colonies from MRS agar with characteristic *L. crispatus* morphology

(e.g., **Figure 3D**). After sub-culture for 3-7 days, colonies of the subcultured bacteria were picked into

MRS broth (for colonies isolated on MRS agar) or into both NYCIII broth and Wilkens-Chalgren broth in

parallel and incubated for 1-4 days, depending on growth rate. The resulting liquid cultures were then

cryopreserved, with aliquots of each culture centrifuged and pellets saved for genomic DNA extraction

and sequencing (see below).

**Nucleic acid extraction for short-read sequencing**

Total nucleic acids (TNA) extraction from cervicovaginal swabs for microbiota profiling was performed via

a phenol-chloroform method, which includes a previously described bead beating process to disrupt

bacteria[70] and modified for processing in 96-well plate format (Phenol:Chloroform:IAA, 25:24:1, pH 6.6,

Invitrogen, #AM9730, which has since been discontinued; Sodium Dodecyl Sulfate 20% Solution, Fisher

Scientific, #BP1311-200; EDTA, Invitrogen, #AM9260G; 2-Propanol, Sigma, #I9516-500ML; 3M Sodium

Acetate, pH 5.5, Life Technologies, #AM9740). Aliquoted samples were thawed on ice, then TNA

extraction was performed using 200uL of well-mixed Star media. The extracted TNA sample was eluted

into 80uL of TE buffer (Promega, #V6321).

To extract bacterial genomic DNA (gDNA) for genome sequencing of cultured bacterial strains, each

isolated strain was streaked on the indicated solid media and a single, clonal colony was picked into broth

culture and incubated in static culture under anaerobic conditions for between 18 and 120 hours

(depending on strain growth kinetics). Cultures were centrifuged and gDNA was extracted from the pellets

using a plate-based protocol including a bead beating process and combining phenol-chloroform

isolation[70] with QIAamp 96 DNA QIAcube HT kit (Qiagen, # 51331) procedures.

**Bacterial 16S ribosomal RNA (rRNA) gene amplification and sequencing**

Bacterial microbiota taxonomic composition in cervicovaginal samples was determined by sequencing

the V4 region of the bacterial 16S rRNA gene. The V4 region was amplified via polymerase chain reaction

(PCR)   using   the   primer   set   515F/806R   at   200   pM   each   (515F   primer   sequence

5'-    AATGATACGGCGACCACCGAGACGTACGTACGGT<u>GTGCCAGCMGCCGCGGTAA</u>-3'    and

barcoded              806R              primer              sequence              5'-

CAAGCAGAAGACGGCATACGAGATXXXXXXXXXXXXXAGTCAGTCAGCC<u>GGACTACHVGGGTWTCT</u>

<u>AAT</u>-3', in which the underlined sequences in each primer represent the regions of complementarity to

5' and 3' ends of the V4 region of the bacterial 16S rRNA gene, respectively, and the barcode positions

in the 806R primer are indicated by X; IDT), with the 806R primers barcoded for multiplexing[34,71]. PCR

was performed in 25 µl reactions containing 1X Q5 reaction buffer (NEB, #B9027), 0.2 mM of dNTPs

(NEB, #N0447), 0.2 µM of each primer, 0.5 unit of Q5 high-fidelity DNA polymerase (NEB, #M0491), and

2 µl of the TNA sample. PCR was performed in triplicate for each sample in the following program: 98°C

for 30 seconds, followed by 30 cycles of 98°C for 10 seconds, 60°C for 30 seconds, and 72°C for 20

seconds, followed by a final extension at 72°C for 2 minutes. The triplicate PCR reactions for each sample

were combined and amplicon production and size were confirmed on an agarose gel. Negative controls

with PCR-quality water (Invitrogen, #10977) as a template were amplified in parallel for each primer

barcode mix and assessed in parallel by gel electrophoresis to confirm absence of contamination and

non-specific amplification. PCR products were pooled, with the amount for each sample semi-

quantitatively adjusted based on its gel band intensity, then purified with a QIAquick PCR purification kit

(Qiagen, #28104)  and quality controlled with the Qubit™ 4 Fluorometer (Invitrogen #Q33226), and

TapeStation (Agilent Technologies, 4200 TapeStation). Libraries were mixed with 10% PhiX and single-

end sequenced on an Illumina MiSeq using a 300-cycle v2 kit (Illumina, #MS-102-2002) employing the

custom Earth Microbiome Project sequencing primers (Read 1 sequencing primer sequence: 5'-

ACGTACGTACGGTGTGCCAGCMGCCGCGGTAA-3'; read 2 sequencing primer sequence: 5'-

ACGTACGTACCCGGACTACHVGGGTWTCTAAT-3'; index sequencing primer sequence:

5'- ATTAGAWACCCBDGTAGTCCGGCTGACTGACT-3'; IDT)[71]. Negative controls for TNA extractions

and PCRs were included in each sequencing library. Study samples were sequenced in a total of six

libraries. Samples with read counts < 10,000 in initial libraries were re-amplified and re-pooled into

subsequent libraries and data from the run producing the highest number of reads for each sample (if the

sample was sequenced multiple times) were selected for subsequent analysis. Analyzable 16S rRNA

gene data was generated from a total of 1152 out of 1156 available trial samples, with the remaining 4

samples failing due to technical challenges with extraction, amplification, or sequencing.

**Bacterial short-read shotgun whole genome library preparation and sequencing**

Shotgun metagenomic and genomic libraries were prepared following a modified protocol of Baym et.

al[72], using the Nextera DNA Library Preparation Kit (Illumina, #20034211) and KAPA HiFi Library

Amplification Kit (Kapa Biosystems, #KK2602). In brief, DNA from each sample was standardized to a

concentration of 1ng/mL after quantification with SYBR Green (Invitrogen, #S7653), followed by

simultaneous fragmentation and sequencing adaptor incorporation by mixing 1ng of DNA (1 mL) with

1.25 ml TD buffer and 0.25 mL TDE1 provided in the Nextera kit and incubating for 9min at 55°C.

Tagmented DNA fragments were amplified in PCR using the KAPA high fidelity library amplification

reagents, with Illumina adaptor sequences and sample barcodes incorporated in primers. PCR products

were pooled, purified with magnetic beads (MagBio Genomics #AC-60050) and paired-end sequenced

on Illumina NovaSeq X with a 300-cycle kit (Psomagen, Inc.).

**Bacterial 16S rRNA gene sequence processing and annotation**

Demultiplexing of Illumina MiSeq bacterial 16S rRNA gene sequence data was performed using QIIME

1 version 1.9.188[73]. Mapping files created in QIIME 1 format were validated using

validate_mapping_file.py, then sequences were demultiplexed with split_libraries_fastq.py using

parameter store_demultiplexed_fastq and no quality filtering or trimming, and demultiplexed sequences

were organized into individual fastq files using split_sequence_file_on_sample_ids.py. Sequence reads

were trimmed and filtered using dada2 version 1.6.0[74], trimming at positions 10 (left) and 230 (right) using

the filterAndTrim function with truncQ = 11, MaxEE = 2, and MaxN = 0. Sequences were then inferred,

then initial taxonomy assigned using the dada2 assignTaxonomy function with the RDP training database

rdp_train_set_16.fa.gz (https://www.mothur.org/wiki/RDP_reference_files). Amplicon sequence variant

(ASV) taxonomic assignments were refined via extensive manual review. The resulting annotated

sequences were analyzed in R using phyloseq version 1.30.0[75] and custom R scripts. Sequence

processing and taxonomy assignment was performed blinded to information about participants' and

samples' clinical and demographic characteristics, treatments, and trial outcomes.

**Total bacterial load via qPCR**

Quantification of total bacterial load via qPCR was performed and reported as part of the initial LACTIN-

V clinical trial[36]. In brief, DNA extracted from samples stored in the Copan ESwab® system were amplified

using bacterial 16S rRNA gene primers targeting total bacteria (16S ribosomal DNA,

AGAGTTTGATCCTGGCTCAG, GCTGCCTCCCGTAGGAGT, 312bp). Bacterial concentration was

calculated using a standard curve based on serial dilutions of the CTV-05 strain as previously described[36].

**Assessing balance between arms at the pre- and post-MTZ visits.**

Since pre-intervention (*i.e.,* pre-MTZ or post-MTZ) microbiota composition may be associated with

differential microbiota composition post-intervention, imbalances between arms could lead to biases in

our primary outcome benefit ratio estimates. To assess whether significant imbalances in microbiota

composition existed in this cohort, we performed a PERMANOVA analysis, as implemented in the vegan

R package, to test whether the intervention arm (LBP *vs* placebo) explained significant variability in

microbiota β-diversity, computed using the Bray-Curtis dissimilarity on ASV relative abundances.

**Benefit Ratios**

667 Benefit ratios, and associated confidence intervals and *p*-value were computed using Wald's method as

668 implemented in the epitools R package[76].

**Identification of microbiota topics from 16S rRNA gene sequencing count data**

Microbiota topics were identified using a similar approach as in[45]. One main difference is that here,

*Lactobacillus* topics (i.e., topics composed exclusively of *Lactobacillus* species) were defined

independently from non-*Lactobacillus* topics (*i.e.,* topics composed exclusively of non-*Lactobacillus*

species), which were identified by fitting a Latent Dirichlet Allocation model[48] to the non-*Lactobacillus*

ASV counts aggregated at the species level. This was done to facilitate the interpretation of topic

composition and, specifically, to allow for "pure" topics for the most prevalent *Lactobacillus* species in

this cohort (*L. crispatus*, *L. iners*, and *L. jensenii*).

To determine *K*, the optimal number of non-*Lactobacillus* topics, we relied on a method called "topic

alignment"[77] which examines the robustness of topics across resolutions (increasing values of *K*) and

provides diagnostics scores that facilitate the identification of spurious topics. We selected *K* to minimize

the number of spurious topics (flagged by low coherence scores) and such that the number of paths

(collection of similar topics across resolution) in the alignment presented a plateau[77] (**Figure S2A**-**B**).

The estimated proportions (relative abundances) of non-*Lactobacillus* topics in each sample ($\hat{p}_{ki}$ where

$k$ is the topic and $i$ is the sample) were computed by multiplying the proportions estimated by the model

on non-*Lactobacillus* counts ($\hat{\pi}_{ki}$) by the total non-*Lactobacillus* proportions in each samples ($\widehat{\Pi}_i =$

$\sum_{v \in V} \quad p_{vi}$ where $p_{vi}$ is the observed proportion of ASV $v$ in sample $i$ and $V$ is the set of non-*Lactobacillus*

ASVs, such that $\hat{p}_{ki} = \hat{\pi}_{ki} \, \widehat{\Pi}_i$).

*Lactobacillus* topics were defined as follows: *Lactobacillus* species which reached 50% of a microbiota

composition in at least 10 samples made up their own topic, while the remaining *Lactobacillus* species

were grouped into a single topic ("Other *L.*") as their total prevalence and abundance was overall small

(**Figure S2C**). The composition of this topic was estimated from the species average prevalences in this

cohort. The estimation of proportions of *Lactobacillus* topics in each sample was straightforward: they

were computed from the proportions of the corresponding species in each sample.

**Isolate genome assemblies from short-read sequencing**

Paired-end short-read genomic sequencing data from bacterial isolates were processed through a quality

control and assembly pipeline. Raw reads were first trimmed for adapter sequences using Cutadapt v4.6

with the Nextera adapter sequence (CTGTCTCTTAT). Quality filtering was then performed using Sickle-

trim v1.33 with a quality threshold of Q20 and minimum read length of 50 bp after trimming. Read quality

was assessed using FastQC. De novo genome assembly was performed using Unicycler v0.5.0 in

standard mode with default parameters. Unicycler produces high-quality assemblies from short reads

alone by optimizing SPAdes assembly, followed by graph simplification. The resulting assemblies were

annotated using Bakta v1.9.4 with the Bakta database v5, which provides comprehensive bacterial

genome annotation including coding sequences, rRNAs, tRNAs, and other genomic features. Assembly

completeness and quality were evaluated using BUSCO v5.5 with the Bacteroidales lineage dataset

(bacteroidales_odb10), providing a measure of genome completeness based on conserved single-copy

orthologs.

**Strain CTV-05 long-read DNA extraction, sequencing, and completed genome assembly**

For long-read (Oxford Nanopore Technologies) genome sequencing of the CTV-05 strain, a bacterial

pellet was prepared from a clonal colony cultured in *Lactobacillus* MRS broth media as described above.

gDNA was extracted using a non-bead-beating protocol to minimize shearing of DNA fragments, with

extractions performed and sequenced using five parallel aliquots of the same original broth culture to

maximize yield and consistency. Since *L. crispatus* is known to have a thick cell wall containing surface-

layer (S-layer) proteins, cell pellets were resuspended with 5M lithium chloride (Molecular Dimensions

#MD2-100-43) and then washed with PBS to begin to degrade the cell wall. Using the manufacturer's

protocol for the MasterPureTM Gram Positive DNA Purification Kit (Biosearch Technologies

#MGP04100), the bacterial cells were then lysed, proteins and RNA were digested, and genomic DNA

(gDNA) was extracted. Extracted gDNA concentration was diluted 1:5 and measured using the Qubit™

4 Fluorometer, then DNA libraries were prepared using Oxford Nanopore Sequencing's Rapid Barcoding

Kit (Oxford Nanopore Technologies #SQK-RBK004; note that this product has been discontinued as of

March 2024). In brief, 400 ng of gDNA from five replicate extractions was barcoded, pooled, purified, and

then loaded onto the MinION Flow Cell using R9.4.1 chemistry (Oxford Nanopore Technologies #FLO-

MIN106D; note that this product has been discontinued as of July 2024) in the MinION Sequencing

Device (Oxford Nanopore Technologies #MIN-101B). To produce the maximum number of reads possible

using the Rapid Barcoding Kit, the sequencing run was continued for a full 72 hours.

Demultiplexed genomic long-reads from MinKNOW v2.2 were concatenated, and reads were separately

filtered for quality and length using Filtlong v0.2.1 (https://github.com/rrwick/Filtlong). Filtered reads were

subsampled to make 12 different read sets using Trycycler v0.5.3[78] and duplicate reads from each read

set were removed using BBMap v39.00[79]. The read sets were assembled using Flye v2.9.1[80], Minipolish

v0.1.3[81], Raven v1.8.1[82], and Canu v2.2[83]. Contigs from different assembly methods were clustered

based on similarity to generate consensus sequences and improve assembly quality using Trycycler.

Clusters were manually chosen and Trycycler was used to reconcile the contigs within each cluster.

Multiple sequence alignment and read partitioning were performed on the reconciled contigs using

Trycyler to understand sequence variation within each cluster and assign each read to the cluster it best

aligned with respectively. Trycycler was then used to generate a consensus contig sequence for each

cluster based on the multiple sequence alignment and read partitioning steps. Medaka v1.7.2

(https://github.com/nanoporetech/medaka), a tool for creating consensus sequences specifically from

nanopore sequence data, was used to polish the Trycycler consensus sequences. The consensus

sequences were then combined, after which Polypolish v0.5.0[84] was used to polish the long-read

sequence with Illumina short-read data generated from an aliquot of the same clonal culture of CTV-05

(extracted and sequenced as described above). The complete CTV-05 genome was annotated using

Bakta v1.7.0[85] and published online as part of this manuscript under NCBI BioProject reference number:

PRJNA1303956.

**Construction of *L. crispatus* core SNP database for strain analysis**

A GT-Pro database of biallelic core sites was constructed using 236 *L. crispatus* genomes using k-mers

with thresholds for SNP prevalence of 0.95 and minor allele frequencies of 0.02 with MAAST[50,86,87]. Then

k-mers for samples were counted to generate a metagenotype, or a matrix of the number of reads at

biallelic SNP sites for a single species[49]. This matrix was then used by StrainFacts to infer suitable allele

and relative abundance matrices that represent strains across all given samples[50].

***L. crispatus* strain estimation in metagenomes**

Raw metagenomic paired-end reads from vaginal swab samples were quality-trimmed and adapter-

filtered using Cutadapt (v3.9)[88]. Human reads were depleted by aligning reads to the T2T-CHM13

reference genome using HISAT2 (v2.2.1)[89]. Processed reads were profiled using GT-Pro (v1.0.1) against

the custom SNP database[87]. Resulting metagenotype profiles were analyzed with StrainFacts (v0.6.0) to

infer strain genotypes and abundances for *L. crispatus*, excluding samples with <25% coverage of the

biallelic SNPs[49]. The fit was then run through a cleanup step to remove low abundance strains and strains

with extremely similar genotypes using sfacts cleanup_fit --abundance 0.01 --dissimilarity 0.01 --

discretized. Analysis was performed on samples with ≥5% overall relative abundance of *L. crispatus* as

determined by 16S rRNA gene sequencing based on evaluations of parameters supporting accurate

StrainFacts LBP strain inference[50]. *L. crispatus* strain inference was successful in 313 of 343 samples in

which species relative abundance exceeded the analysis threshold, while strain analysis was

unsuccessful in the remaining 30 samples due to failed or inadequately deep shotgun metagenomic

sequencing. A 10% strain proportional abundance was used as a threshold for confident strain

identification based on prior simulations and experimental validation[50].

**Strain analysis of isolate genomes and comparison to metagenomically inferred strain genotypes**

Isolate genomes were taxonomically identified using GTDB-Tk v2[90]. Gene-calling was performed for *L.*

*crispatus* isolate genomes, including the completed CTV-05 genome (see above) using Prodigal[91]. Core

ribosomal proteins were identified using HMMER[92], aligned using mafft[93,94], then concatenated and a

phylogenetic tree was constructed using fasttree[95,96], which was used to compute branch lengths to

identify isolates representing distinct strains and determine which isolates represented CTV-05 or

endogenous strains. GT-Pro[87] was then used to calculate genotypes from representative isolate reads

for comparison to metagenomically inferred strain genotypes, calculated based on Jaccard similarity of

the StrainFacts genotypes[50].

**Measurement of vaginal mucosal cytokines and chemokines.**

Cytokines and chemokines were measured using a previously described custom 20-plex High Sensitivity

Luminex Assay Kit from EMD Millipore that measures interferon gamma-induced protein (IP-10),

interleukin 8 (IL-8), interleukin 6 (IL-6), monokine induced by interferon gamma (MIG), interferon-

inducible T cell alpha chemoattractant (ITAC), interleukin 1 alpha (IL-1α), interleukin 1 beta (IL-1β),

macrophage inflammatory protein-1 alpha (MIP-1α), macrophage inflammatory protein-1 beta (MIP-1β),

macrophage inflammatory protein-3 alpha (MIP-3α), tumour necrosis factor alpha (TNFα), interleukin 21

(IL-21), interleukin 17 (IL-17), interferon gamma (IFNγ), interleukin 23 (IL-23), interleukin 12 (IL-12 p70),

interleukin 13 (IL-13), interleukin 10 (IL-10), interleukin 4 (IL-4), and interleukin 5 (IL-5)[6]. Reagents were

used as supplied by the manufacturer, except the Mixed Beads solution, detection antibody mixture, and

Streptavidin-phycoerythrin (Strep-PE) were diluted 3-fold (1:2 volume:volume ratio) for use. The Mixed

Beads were diluted in Bead Diluent, while the detection antibodies and Strep-PE were diluted individually

in Assay Buffer. All reagents were from a single manufacturer lot to minimize batch effects.

Samples were first pre-processed to remove interfering mucus and debris. In brief, 200 $\mu$L aliquots of

each vaginal swab supernatant were thawed on ice, vortexed for 10 seconds to resuspend, then

centrifuged at 1000 rcf for 15 minutes at 4°C to pellet mucous and cells. The maximum amount of

supernatant recoverable from each sample without disturbing the resulting pellet was then transferred to

a well of a 0.22 m PVDF filter plate (EMD Millipore #MSGVS2210), filtered by centrifugation at 2,451 rcf

for 1 hour at 4°C, then transferred to freezer-safe tubes and stored at -80°C until assayed. Samples were

assayed in 96-well plates as per manufacturer protocol with the addition of periodic sonication steps to

minimize bead clumping. Each plate assay included one blank background control, 7 standard serial

dilutions assayed in duplicate, two manufacturer-supplied Quality Control (QC) samples assayed in

duplicate, 72 experimental samples, and 4 biological control samples used as internal quality controls on

all plates. Batches of standards and QC samples were prepared from the kit on the day of the assay

according to manufacturer protocol. For each sample or standard, 25 $\mu$L each of Assay Buffer, Mixed

Beads, and sample were aliquoted into each plate well. After the addition of Mixed Beads, all incubation

steps were performed while the plate was protected from light. Plates were sonicated for 30 seconds at

room temperature in a bath sonicator, then incubated for 16-18 hours on a horizontal plate shaker at 600

rpm in 4°C. An additional 30 second sonication at room temperature was then performed. A handheld

plate magnet was applied to the base of the plate to retain the magnetic beads and excess sample and

reagents were removed via three consecutive washes using manufacturer-supplied 1X Wash Buffer.

Detection antibodies were added as per manufacturer protocol and plates were incubated for 1 hour at

room temperature on a horizontal plate shaker at 600 rpm. Next, Strep-PE reagent was added, followed

by a 30 minute incubation at room temperature on a horizontal plate shaker at 600 rpm. Plates were

washed 3 times as above using the magnet. After the final wash, 150 $\mu$L of sheath fluid was added to all

wells and a final 30 second sonication at room temperature was performed. Analyte concentrations were

measured using a FLEXMAP 3D instrument with Luminex xPONENT software.

**Cytokine and chemokine concentration transformations**

Cytokine and chemokine concentrations were log-transformed (log) to stabilize the mean-variance

relationship. Compounds with concentration values below the lower limit of quantification (LLOQ) were

imputed at half the LLOQ; those with concentration values above the upper limit of quantification (ULOQ)

were imputed at the ULOQ (**Figure S4A**).

Measurement of soluble molecules in swab samples can be complicated by a "size effect" phenomenon

whereby a component of between-swab variation in concentrations is due to technical differences in the

amount of material collected on each swab. In such situations, the first principal component (PC1), which

reflects the "size" of observations[51], can primarily be driven by the amount of material on the swab rather

than biological variation. Consistent with this size effect phenomenon, we observed that per-sample

cytokine/chemokine concentrations were highly collinear, with PC1 of the standardized log-transformed

cytokine concentrations accounting for over 50% of the total variance (**Figure S4B**) but showed no

substantial correlation with clinical and biological factors such as proportions of total *Lactobacillus* or of

*Lactobacillus crispatus*, or participants' contraceptives (**SI**). Such size effects can be addressed by

subtracting PC1 from the data. We therefore performed PC1 subtraction by re-assigning scores

corresponding to the 1st PC to a value of 0, then transforming the data back to its original variable space

using the transposed rotation matrix (**SI**). Sensitivity analyses were performed to assess the impact of

this transformation on findings (**SI**). Finally, due to the large uncertainty regarding their distributions,

cytokines with values below the LLOQ in ≥60% of the samples or with values above the ULOQ in ≥30%

of the samples were excluded from the analysis (**Figure S4A**).

**Associations between microbiota composition and cytokine profiles**

To quantify the association between microbiota composition and cytokine profiles, we computed the RV

coefficient between the microbiota composition as expressed as topic proportions and cytokine

transformed log10-concentrations. Associated *p*-value was computed with a permutation test[97,98]. To

confirm that correlation between these tables was not driven by potential subject (longitudinal) effects,

we also computed correlation between the two tables at each visit independently. If correlations were

found significant, further analyses were carried out to characterize the relationship between tables.

Specifically, DISTATIS[55,99], as implemented in the distatisR R package, was used. This method presents

the advantage of estimating compromise scores (and partial residual scores) directly from dissimilarity

matrices such that ecological measures of (dis)similarity, such as the Bray-Curtis dissimilarity, can be

used for representing microbiota composition. Associations with the original variables can then be

assessed using correlations and displayed in correlation circles as typically done with PCA, PCoA, or

NMDS results. The minimum number of components used for display was chosen based on the presence

of an elbow in the DiSTATIS scree plot.

**Estimating effect heterogeneity**

Binary outcomes (Y: ≥50% colonization by *L. crispatus* at week 12 or 24 or absence of rBV by week 12

or 24) were predicted using logistic regression (logit link function) with input variables representing the

intervention arm (*A*: LBP or placebo), the baseline (pre-MTZ) microbiota (*V*: stratified by most prevalent

genus, CST, or topic proportions), and their interactions (*A:V*). In stratification analyses, strata with less

than two participants per arm were excluded from the analysis and visualizations. Since *Lactobacillus*

species other than *L. iners* had low pre-MTZ relative abundance, prior to determining fits relying on topic

proportions, *Lactobacillus*-dominated topics were agglomerated such that the proportion of total

*Lactobacillus* was considered, which improved fit convergence. The statistical significance of effect

heterogeneity was tested by comparing the null model (which only includes the intervention arm as

predictor) with the full model where pre-MTZ microbiota and interaction effects were included (analysis

of deviance F test). *P*-values were adjusted to account for multiple hypotheses testing using the

Benjamini-Hochberg procedure[100]. For the stratified analyses, CI were computed using Wilson scores

due to the small sample size in each stratum. When pre-MTZ microbiota composition was included as a

quantitative multivariate variable, counterfactual probabilities of success and associated 95% confidence

intervals were predicted from the logistic regression fitted model by setting the intervention arm to LBP

or placebo. The predicted participant-level odd ratios were computed as the ratio between predicted odds

of *L. crispatus* colonization at week 12 and 24 or rBV by week 12 or 24 had participants been receiving

LBP or the placebo.

**Identifying factors associated with successful *L. crispatus* colonization in intervention arm**

To identify demographic, clinical, behavioral, or microbiologic factors associated with successful *L.*

*crispatus* colonization (≥ 50%) in the intervention arm, we relied on a multiblock partial least square

discriminant analysis (MB-PLS-DA)[101] where the 3-category response variable indicated whether (1)

relative abundance of *L. crispatus* was ≥50%, (2) relative abundance of total *Lactobacillus* (any species)

was ≥50% but relative abundance of *L. crispatus* was <50%, or (3) the relative abundance of total

*Lactobacillus* was <50%. MB-PLS-DA relies on the same principles as PLS-DA but allows for explanatory

variables to be grouped into several thematic blocks, which enables the computation of block importance

indices and covariances with the response block[101,102]. The description of each block and associated

variables is provided in Table S6.

Several explanatory variables were correlated. For example, the abundances of some cytokines

correlated with microbiota composition (**Figure 4**), and the baseline α-diversity was lower in White

participants (**Figure S7C**, p-value < 0.05). We addressed these existing correlations between explanatory

blocks and/or variables in two different ways depending on our assumptions on the underlying correlation

source or cause. We either relied on nested models to evaluate the additive predictive power of specific

blocks (*e.g.,* demographics) that had variables correlated with microbiological blocks or used one variable

or one block to predict the values of another one and included the residuals instead of the observed

values in the model. This was indicated by the symbol (r) in the variable or block names (see **SI** for

details). We used this approach for the cytokine blocks whose residuals were computed using their PLS-

predicted abundances based on microbiota composition (**SI**). Similarly, we computed residual microbiota

composition, α-diversity, and pH at the previous visit such that topic proportions, α-diversity, or pH were

relative to those expected based on the participants' colonization status at the same visit.

Categorical variables such as race or birth control were included using one-hot encoding, and variables

were standardized. To ensure convergence of the fits in cross-validation or using the bootstrap, we added

Gaussian noise with very small variance ($\sigma_i^2 = 10^{-3}S_i^2$ where $\sigma_i^2$ is the variance of the Gaussian noise

for variable $i$, and $S_i^2$ the empirical variance of  the $i^{th}$ variable) to one-hot encoded variables that had

few participants in some categories.

Given that our categorical response had three categories, we selected two latent components for the MB-

PLS-DA models to avoid overfitting. Further, we performed cross-validation analyses (40 random 75-

25% split into calibration and validation sets) and found that two latent components maximized the mean

average F1 score on the validation sets for all models except for the initial phase of the placebo in which

no variables were found to predict our response, leading to poor and unstable performances in cross-

validation (**Figure S6B** and **S8A**). This was consistent with the presence of an elbow in the screeplots

and robust to other choices of metrics such as accuracy or RMSE (**SI**). Relative cumulative block

importance indices were computed by dividing cumulative block importance, the BIPC as in[101], by the

total inertia of each block, which corresponds to the expected BIPC if all variables had a similar

importance (**SI**).

**Acknowledgments**

We thank members of the Vaginal Microbiome Research Consortium for helpful discussions. Funding

was obtained by D.S.K from the Gates Foundation (INV-033690). S.M.B. was partially supported by NIH

grant 1K08AI171166.

**Author Contributions**

D.S.K., S.P.H., S.M.B., and L.S. conceptualized the research with input from J.E., C.M.M., A.H., and

C.R.H.; D.S.K. and S.P.H. supervised the project; S.M.B., L.S., J.E., J.X., S.H., J.S., and S.P.H.

developed and validated methods and models; S.M.B., J.X., S.H., A.S., C.M.M., T.P.P., A.K., and F.A.H.

generated samples and performed experiments; L.S., S.M.B., J.E., J.S., A.H., A.K., F.A.H., and S.P.H.

performed data analysis; L.S., S.M.B., and D.S.K. led writing of the manuscript with contributions from

S.P.H., J.E., J.X., S.H., C.M.M., A.H., T.P.P., A.K., F.A.H., and C.R.H.; All authors provided critical

feedback on methods, results, analysis, and writing.

**Competing Interests**

C.M.M. has a financial interest in Ancilia Biosciences, a company developing a new class of Live

Biotherapeutics and other bacterial products. C.M.M. interests were reviewed and are managed by MGH

and Mass General Brigham in accordance with their conflict-of-interest policies. C.M.M. serves on the

scientific advisory board for Concerto Bio, has served as a consultant for Scynexis and Ancilia

Biosciences, and has received royalties from Up to Date. C.R.C. has served as a scientific advisor for

Osel, Inc, and Evvy and has stock options from both. The UCSF Conflict of Interest Committee approved

a plan to minimize his potential conflict of interest. T.P.P. is an employee of Osel Inc.

**Data and code availability**

Sequencing data and genome assemblies generated as part of this study are posted under NCBI BioProject reference number: PRJNA1303956. Analysis scripts and SI are available on our publicly available GitHub repository (https://github.com/lasy/IIb-LACTIN-V-omics-reanalysis/).

**References**

1. Peebles, K., Velloza, J., Balkus, J. E., McClelland, R. S. & Barnabas, R. V. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. *Sex. Transm. Dis.* **46**, 304–311 (2019).

2. Workowski, K. A. *et al.* Sexually Transmitted Infections Treatment Guidelines, 2021. *MMWR Recomm. Rep. Morb. Mortal. Wkly. Rep. Recomm. Rep.* **70**, 1–187 (2021).

3. Brusselmans, J., De Sutter, A., Devleesschauwer, B., Verstraelen, H. & Cools, P. Scoping review of the association between bacterial vaginosis and emotional, sexual and social health. *BMC Womens Health* **23**, 168 (2023).

4. Bilardi, J. E. *et al.* The burden of bacterial vaginosis: women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. *PloS One* **8**, e74378 (2013).

5. Anahtar, M. N. *et al.* Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. *Immunity* **42**, 965–976 (2015).

6. Gosmann, C. *et al.* Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women. *Immunity* **46**, 29–37 (2017).

7. Atashili, J., Poole, C., Ndumbe, P. M., Adimora, A. A. & Smith, J. S. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. *AIDS Lond. Engl.* **22**, 1493–1501 (2008).

8. Hillier, S. L. *et al.* A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. *N. Engl. J. Med.* **319**, 972–978 (1988).

9. Leitich, H. & Kiss, H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. *Best Pract. Res. Clin. Obstet. Gynaecol.* **21**, 375–390 (2007).

10. Brusselaers, N., Shrestha, S., van de Wijgert, J. & Verstraelen, H. Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. *Am. J. Obstet. Gynecol.* **221**, 9-18.e8 (2019).

11. Allsworth, J. E. & Peipert, J. F. Prevalence of bacterial vaginosis: 2001-2004 National Health and

Nutrition Examination Survey data. *Obstet. Gynecol.* **109**, 114–120 (2007).

12. Kenyon, C., Colebunders, R. & Crucitti, T. The global epidemiology of bacterial vaginosis: a

systematic review. *Am. J. Obstet. Gynecol.* **209**, 505–523 (2013).

13. Marconi, C., Duarte, M. T. C., Silva, D. C. & Silva, M. G. Prevalence of and risk factors for bacterial

vaginosis among women of reproductive age attending cervical screening in southeastern Brazil.

*Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet.* **131**, 137–141 (2015).

14. Bradshaw, C. S. & Sobel, J. D. Current Treatment of Bacterial Vaginosis—Limitations and Need for

Innovation. *J. Infect. Dis.* **214**, S14–S20 (2016).

15. Bradshaw, C. S. & Brotman, R. M. Making inroads into improving treatment of bacterial vaginosis -

striving for long-term cure. *BMC Infect. Dis.* **15**, 292 (2015).

16. Schwebke, J. R. *et al.* Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A

Randomized, Double-Blind, Placebo-Controlled Trial. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc.*

*Am.* **73**, e672–e679 (2021).

17. Bradshaw, C. S. *et al.* High recurrence rates of bacterial vaginosis over the course of 12 months

after oral metronidazole therapy and factors associated with recurrence. *J. Infect. Dis.* **193**, 1478–

1486 (2006).

18. Munoz, A. *et al.* Modeling the temporal dynamics of cervicovaginal microbiota identifies targets that

may promote reproductive health. *Microbiome* **9**, 163 (2021).

19. Tamarelle, J., Shardell, M. D., Ravel, J. & Brotman, R. M. Factors Associated With Incidence and

Spontaneous Clearance of Molecular-Bacterial Vaginosis: Results From a Longitudinal Frequent-

Sampling Observational Study. *Sex. Transm. Dis.* **49**, 649–656 (2022).

20. DiGiulio, D. B. *et al.* Temporal and spatial variation of the human microbiota during pregnancy.

*Proc. Natl. Acad. Sci.* **112**, 11060–11065 (2015).

21. van Houdt, R. *et al.* Lactobacillus iners-dominated vaginal microbiota is associated with increased

susceptibility to Chlamydia trachomatis infection in Dutch women: a case-control study. *Sex. Transm. Infect.* **94**, 117–123 (2018).

22. Colbert, L. E. *et al.* Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. *Cancer Cell* **41**, 1945-1962.e11 (2023).

23. Norenhag, J. *et al.* The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. *BJOG Int. J. Obstet. Gynaecol.* **127**, 171–180 (2020).

24. Kindinger, L. M. *et al.* The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk. *Microbiome* **5**, 6 (2017).

25. Srinivasan, S. *et al.* Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. *PloS One* **5**, e10197 (2010).

26. Ravel, J. *et al.* Daily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis. *Microbiome* **1**, 29 (2013).

27. Verwijs, M. C., Agaba, S. K., Darby, A. C. & Van De Wijgert, J. H. H. M. Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure. *Am. J. Obstet. Gynecol.* **222**, 157.e1-157.e13 (2020).

28. Joag, V. *et al.* Impact of Standard Bacterial Vaginosis Treatment on the Genital Microbiota, Immune Milieu, and Ex Vivo Human Immunodeficiency Virus Susceptibility. *Clin. Infect. Dis.* **68**, 1675–1683 (2019).

29. Mitchell, C. *et al.* Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study. *Infect. Dis. Obstet. Gynecol.* **2012**, 706540 (2012).

30. Ferris, M. J., Norori, J., Zozaya-Hinchliffe, M. & Martin, D. H. Cultivation-independent analysis of changes in bacterial vaginosis flora following metronidazole treatment. *J. Clin. Microbiol.* **45**, 1016–1018 (2007).

31. Zhu, M. *et al.* Vaginal Lactobacillus fatty acid response mechanisms reveal a metabolite-targeted

strategy for bacterial vaginosis treatment. *Cell* **187**, 5413-5430.e29 (2024).

32. Nilsen, T., Swedek, I., Lagenaur, L. A. & Parks, T. P. Novel Selective Inhibition of Lactobacillus

iners by Lactobacillus-Derived Bacteriocins. *Appl. Environ. Microbiol.* **86**, e01594-20 (2020).

33. Lev-Sagie, A. *et al.* Vaginal microbiome transplantation in women with intractable bacterial

vaginosis. *Nat. Med.* **25**, 1500–1504 (2019).

34. Bloom, S. M. *et al.* Cysteine dependence of Lactobacillus iners is a potential therapeutic target for

vaginal microbiota modulation. *Nat. Microbiol.* **7**, 434–450 (2022).

35. Yockey, L. J. *et al.* Screening and characterization of vaginal fluid donations for vaginal microbiota

transplantation. *Sci. Rep.* **12**, 17948 (2022).

36. Cohen, C. R. *et al.* Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. *N.*

*Engl. J. Med.* **382**, 1906–1915 (2020).

37. Ravel, J. *et al.* Impact of a multi-strain L. crispatus-based vaginal synbiotic on the vaginal

microbiome: a randomized placebo-controlled trial. *NPJ Biofilms Microbiomes* **11**, 158 (2025).

38. Chetty, C. *et al.* Randomized Trial of Multi-Strain Lactobacillus crispatus Vaginal Live

Biotherapeutic Products after Antibiotic Therapy for Bacterial Vaginosis: Study Protocol for

VIBRANT (Vaginal Live Biotherapeutic RANdomized Trial). Preprint at

https://doi.org/10.2139/ssrn.5261044 (2025).

39. Hemmerling, A. *et al.* Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the

prevention of bacterial vaginosis. *Sex. Transm. Dis.* **36**, 564–569 (2009).

40. Amsel, R. *et al.* Nonspecific vaginitis: Diagnostic criteria and microbial and epidemiologic

associations. *Am. J. Med.* **74**, 14–22 (1983).

41. Nugent, R. P., Krohn, M. A. & Hillier, S. L. Reliability of diagnosing bacterial vaginosis is improved

by a standardized method of gram stain interpretation. *J. Clin. Microbiol.* **29**, 297–301 (1991).

42. Robert, P. & Escoufier, Y. A Unifying Tool for Linear Multivariate Statistical Methods: The RV-

Coefficient. *J. R. Stat. Soc. Ser. C Appl. Stat.* **25**, 257–265 (1976).

43. Josse, J. & Holmes, S. Measuring multivariate association and beyond. *Stat. Surv.* **10**, (2016).

44. Sankaran, K. & Holmes, S. P. Latent variable modeling for the microbiome. *Biostatistics* **20**, 599–

614 (2019).

45. Symul, L. *et al.* Sub-communities of the vaginal microbiota in pregnant and non-pregnant women.

*Proc. R. Soc. B Biol. Sci.* **290**, 20231461 (2023).

46. Ravel, J. *et al.* Vaginal microbiome of reproductive-age women. *Proc. Natl. Acad. Sci.* **108**, 4680–

4687 (2011).

47. France, M. T. *et al.* VALENCIA: a nearest centroid classification method for vaginal microbial

communities based on composition. *Microbiome* **8**, 166 (2020).

48. Blei, D. M., Ng, A. Y. & Jordan, M. I. Latent Dirichlet Allocation. *J. Mach. Learn. Res.* 30 (2003).

49. Smith, B. J., Li, X., Shi, Z. J., Abate, A. & Pollard, K. S. Scalable Microbial Strain Inference in

Metagenomic Data Using StrainFacts. *Front. Bioinforma.* **2**, (2022).

50. Shih, J. *et al.* StrainFacts accurately quantifies bacterial strain abundance and dynamics in

simulated and real-world microbiota samples treated with live biotherapeutic products (LBPs).

*Manuscr. Prep.*

51. Jolicoeur, P. & Mosimann, J. E. Size and Shape Variation in The Painted Turtle. A Principal

Component Analysis. *Growth* (1960).

52. Masson, L. *et al.* Defining genital tract cytokine signatures of sexually transmitted infections and

bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. *Sex. Transm.*

*Infect.* **90**, 580–587 (2014).

53. Masson, L. *et al.* Inflammatory cytokine biomarkers of asymptomatic sexually transmitted infections

and vaginal dysbiosis: a multicentre validation study. *Sex. Transm. Infect.* **95**, 5–12 (2019).

54. Abdi, H., Dunlop, J. P. & Williams, L. J. How to compute reliability estimates and display confidence

and tolerance intervals for pattern classifiers using the Bootstrap and 3-way multidimensional

scaling (DISTATIS). *NeuroImage* **45**, 89–95 (2009).

55. Abdi, H., O'Toole, A. J., Valentin, D. & Edelman, B. DISTATIS: The Analysis of Multiple Distance

Matrices. in *2005 IEEE Computer Society Conference on Computer Vision and Pattern Recognition*

*(CVPR'05) - Workshops* vol. 3 42–42 (IEEE, San Diego, CA, USA, 2005).

56. Armstrong, E. *et al.* Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital

immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-

controlled trial. *Lancet Microbe* **3**, e435–e442 (2022).

57. France, M. T. *et al.* VALENCIA: a nearest centroid classification method for vaginal microbial

communities based on composition. *Microbiome* **8**, 166 (2020).

58. Bradshaw, C. S. *et al.* Bacterial vaginosis. *Nat. Rev. Dis. Primer* **11**, 43 (2025).

59. Symul, L. *et al.* Sub-communities of the vaginal microbiota in pregnant and non-pregnant women.

*Proc. R. Soc. B Biol. Sci.* **290**, 20231461 (2023).

60. Lebeer, S. *et al.* A citizen-science-enabled catalogue of the vaginal microbiome and associated

factors. *Nat. Microbiol.* **8**, 2183–2195 (2023).

61. Aldridge, K. E. *et al.* Multicenter survey of the changing in vitro antimicrobial susceptibilities of

clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and

Peptostreptococcus species. *Antimicrob. Agents Chemother.* **45**, 1238–1243 (2001).

62. Alauzet, C. *et al.* Metronidazole resistance in Prevotella spp. and description of a new nim gene in

Prevotella baroniae. *Antimicrob. Agents Chemother.* **54**, 60–64 (2010).

63. Holm, J. B. *et al.* Comparative Metagenome-Assembled Genome Analysis of 'Candidatus

Lachnocurva vaginae', Formerly Known as Bacterial Vaginosis-Associated Bacterium-1 (BVAB1).

*Front. Cell. Infect. Microbiol.* **10**, 117 (2020).

64. Fredricks, D. N., Fiedler, T. L. & Marrazzo, J. M. Molecular Identification of Bacteria Associated with

Bacterial Vaginosis. *N. Engl. J. Med.* **353**, 1899–1911 (2005).

65. Vodstrcil, L. A. *et al.* Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis. *N.*

*Engl. J. Med.* **392**, 947–957 (2025).

66. Zenilman, J. M. *et al.* Condom Use to Prevent Incident STDs: The Validity of Self-Reported

Condom Use. *Sex. Transm. Dis.* **22**, 15 (1995).

67. Schroder, K. E. E., Carey, M. P. & Vanable, P. A. Methodological challenges in research on sexual

risk behavior: I. Item content, scaling, and data analytical options. *Ann. Behav. Med.* **26**, 76–103

(2003).

68. Schroder, K. E. E., Carey, M. P. & Vanable, P. A. Methodological challenges in research on sexual

risk behavior: II. Accuracy of self-reports. *Ann. Behav. Med.* **26**, 104–123 (2003).

69. Jewanraj, J. *et al.* The Impact of Semen Exposure on the Immune and Microbial Environments of

the Female Genital Tract. *Front. Reprod. Health* **2**, 566559 (2020).

70. Anahtar, M. N., Bowman, B. A. & Kwon, D. S. Efficient Nucleic Acid Extraction and 16S rRNA Gene

Sequencing for Bacterial Community Characterization. *J. Vis. Exp. JoVE* 53939 (2016)

doi:10.3791/53939.

71. Caporaso, J. G. *et al.* Global patterns of 16S rRNA diversity at a depth of millions of sequences per

sample. *Proc. Natl. Acad. Sci. U. S. A.* **108 Suppl 1**, 4516–4522 (2011).

72. Baym, M. *et al.* Inexpensive multiplexed library preparation for megabase-sized genomes. *PloS*

*One* **10**, e0128036 (2015).

73. Caporaso, J. G. *et al.* QIIME allows analysis of high-throughput community sequencing data. *Nat.*

*Methods* **7**, 335–336 (2010).

74. Callahan, B. J. *et al.* DADA2: High-resolution sample inference from Illumina amplicon data. *Nat.*

*Methods* **13**, 581–583 (2016).

75. McMurdie, P. J. & Holmes, S. phyloseq: an R package for reproducible interactive analysis and

graphics of microbiome census data. *PloS One* **8**, e61217 (2013).

76. Aragon, T. J. epitools: Epidemiology Tools. 0.5-10.1

https://doi.org/10.32614/CRAN.package.epitools (2004).

77. Fukuyama, J., Sankaran, K. & Symul, L. Multiscale analysis of count data through topic alignment.

*Biostatistics* **24**, 1045–1065 (2023).

78. Wick, R. R. *et al.* Trycycler: consensus long-read assemblies for bacterial genomes. *Genome Biol.*

**22**, 266 (2021).

79. Bushnell, B. BBMap:  A Fast, Accurate, Splice-Aware Aligner. in *Report Number: LBNL-7065E*

(Research Org.: Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States), 2014).

80. Kolmogorov, M., Yuan, J., Lin, Y. & Pevzner, P. A. Assembly of long, error-prone reads using

repeat graphs. *Nat. Biotechnol.* **37**, 540–546 (2019).

81. Wick, R. R. & Holt, K. E. Benchmarking of long-read assemblers for prokaryote whole genome

sequencing. *F1000Research* **8**, 2138 (2021).

82. Vaser, R. & Šikić, M. Time- and memory-efficient genome assembly with Raven. *Nat. Comput. Sci.*

**1**, 332–336 (2021).

83. Koren, S. *et al.* Canu: scalable and accurate long-read assembly via adaptive *k* -mer weighting and

repeat separation. *Genome Res.* **27**, 722–736 (2017).

84. Wick, R. R. & Holt, K. E. Polypolish: Short-read polishing of long-read bacterial genome

assemblies. *PLOS Comput. Biol.* **18**, e1009802 (2022).

85. Schwengers, O. *et al.* Bakta: rapid and standardized annotation of bacterial genomes via

alignment-free sequence identification: Find out more about Bakta, the motivation, challenges and

applications, here. *Microb. Genomics* **7**, (2021).

86. Shi, Z. J., Nayfach, S. & Pollard, K. S. Maast: genotyping thousands of microbial strains efficiently.

*Genome Biol.* **24**, 186 (2023).

87. Shi, Z. J., Dimitrov, B., Zhao, C., Nayfach, S. & Pollard, K. S. Fast and accurate metagenotyping of

the human gut microbiome with GT-Pro. *Nat. Biotechnol.* **40**, 507–516 (2022).

88. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads.

*EMBnet.journal* **17**, 10 (2011).

89. Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based genome alignment and

genotyping with HISAT2 and HISAT-genotype. *Nat. Biotechnol.* **37**, 907–915 (2019).

90. Chaumeil, P.-A., Mussig, A. J., Hugenholtz, P. & Parks, D. H. GTDB-Tk v2: memory friendly

classification with the genome taxonomy database. *Bioinformatics* **38**, 5315–5316 (2022).

91. Hyatt, D. *et al.* Prodigal: prokaryotic gene recognition and translation initiation site identification.

*BMC Bioinformatics* **11**, 119 (2010).

92. Eddy, S. R. HMMER. (2023).

93. Katoh, K., Rozewicki, J. & Yamada, K. D. MAFFT online service: multiple sequence alignment,

interactive sequence choice and visualization. *Brief. Bioinform.* **20**, 1160–1166 (2019).

94. Kuraku, S., Zmasek, C. M., Nishimura, O. & Katoh, K. aLeaves facilitates on-demand exploration of

metazoan gene family trees on MAFFT sequence alignment server with enhanced interactivity.

*Nucleic Acids Res.* **41**, W22–W28 (2013).

95. Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree 2 – Approximately Maximum-Likelihood Trees for

Large Alignments. *PLoS ONE* **5**, e9490 (2010).

96. Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree: Computing Large Minimum Evolution Trees with

Profiles instead of a Distance Matrix. *Mol. Biol. Evol.* **26**, 1641–1650 (2009).

97. Dray, S. & Dufour, A.-B. The **ade4** Package: Implementing the Duality Diagram for Ecologists. *J.*

*Stat. Softw.* **22**, (2007).

98. Bougeard, S. & Dray, S. Supervised Multiblock Analysis in *R* with the **ade4** Package. *J. Stat. Softw.*

**86**, (2018).

99. Abdi, H., Williams, L. J., Valentin, D. & Bennani-Dosse, M. STATIS and DISTATIS: optimum

multitable principal component analysis and three way metric multidimensional scaling. *WIREs*

*Comput. Stat.* **4**, 124–167 (2012).

100.    Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful

Approach to Multiple Testing. *J. R. Stat. Soc. Ser. B Methodol.* **57**, 289–300 (1995).

101.    Brandolini-Bunlon, M. *et al.* Multi-block PLS discriminant analysis for the joint analysis of

metabolomic and epidemiological data. *Metabolomics* **15**, 134 (2019).

102.    Bougeard, S., Qannari, E. M. & Rose, N. Multiblock redundancy analysis: interpretation tools

and application in epidemiology. *J. Chemom.* **25**, 467–475 (2011).

1152

1153 **Main Tables and Figures**

1154 **Table 1: Benefit ratios for LBP microbiota effects**

| Taxon | Week | Microbiota Endpoint | LACTIN-V | Placebo | Benefit Ratio (95% CI) | P Value |
|---|---|---|---|---|---|---|
| *L. crispatus* | Week 12 | ≥ 50% *L.c.* | 37 (30%) | 5 (9%) | 3.37 (1.40 - 8.11) | < 0.005 |
| | | < 50% *L.c.* | 86 (70%) | 51 (91%) | | |
| | Week 24 | ≥ 50% *L.c.* | 39 (35%) | 4 (8%) | 4.49 (1.69 - 11.90) | |
| | | < 50% *L.c.* | 74 (65%) | 48 (92%) | | |
| *Lactobacillus* | Week 12 | ≥ 50% *Lacto* | 69 (56%) | 27 (48%) | 1.16 (0.85 - 1.59) | |
| | | < 50% *Lacto* | 54 (44%) | 29 (52%) | | |
| | Week 24 | ≥ 50% *Lacto* | 65 (58%) | 17 (33%) | 1.76 (1.15 - 2.68) | |
| | | < 50% *Lacto* | 48 (42%) | 35 (67%) | | |

1155 Benefit Ratios and associated 95% confidence intervals were computed using Wald's method.

1156 **Figure 1: LACTIN-V trial design and microbiota endpoints**

1157

A. Schematic of LACTIN-V trial study design and sampling visit timing.

B. Participants were grouped into three microbiota categories: *L. crispatus*-dominant colonization (≥

50% *L. crispatus* relative abundance), *Lactobacillus* (non-*crispatus*)-dominant colonization (≥

50% *Lactobacillus,* < 50% *L. crispatus*), or non-*Lactobacillus*-dominant (< 50% *Lactobacillus*)

based on results of bacterial 16S rRNA gene sequencing. The Sankey diagram displays how

participants transitioned between these three categories throughout the trial.

C. Microbiota composition and BV diagnosis at week 12 for each participant in the LBP and placebo

treatment arms. Relative abundances of the 15 most abundant taxa are shown, with remaining

taxa summed as "Other". Participants are grouped by treatment arm into the categories defined

as in **Figure 1B,** with BV diagnosis indicated along the top margin.

D. Total bacterial load (measured by qPCR) at each scheduled visit in each arm. Boxplots (here and

in subsequent figures) represent the median (middle horizontal line), the 25th and 75th percentiles

(lower and upper boundaries of boxes, respectively, "IQR"), measurements that fall within 1.5

times the IQR (whiskers), and any individual measurement outside that range (dots).

**Figure 2: Microbiota trajectories throughout the trial**

1173

A. Proportion of each taxon (y-axis) in each non-*Lactobacillus* topic (x-axis) as estimated by Latent

Dirichlet Allocation (LDA) from 16S rRNA gene sequencing data. Proportions sum to one for each

topic. Taxa were included if they made up at least 1% of any topic and non-*Lactobacillus* topics

are named according to their most predominant taxon. "*G. s/l*": *Gardnerella swidsinskii-leopoldii*.

"*P. amnii*": *Prevotella amnii*. "*Ca.* L. v. (BVAB1)": *Candidatus* Lachnocurva vaginae (BVAB1). "*P.*

*bivia*": *Prevotella bivia*.

B. Microbiota composition expressed as topic relative abundance (x-axis) for each participant at

each scheduled visit. Results are depicted for participants with microbiota compositional data for

at least three of the six visits. Results are grouped by visit (horizontal panels) and treatment arm

(vertical panels), and the y-axis is ordered by microbiota composition trajectories (see **SI**).

C. Relative abundance of each topic (horizontal panels) in each arm (vertical panels) at each visit.

Samples from the same participant are connected by a line.

D. Bray-Curtis dissimilarity between each participant's microbiota composition at the two indicated

consecutive visits, calculated from 16S rRNA gene amplicon sequence variant (ASV) relative

abundances. For each pair of consecutive visits, values are shown only for participants with

available microbiota data from both visits.

**Figure 3: *L. crispatus* strain dynamics among LBP recipients**

A.   Sankey diagram showing dynamics of CTV-05 versus non-CTV-05 *L. crispatus* strain colonization

among LBP recipients. Strains were inferred from shotgun metagenomic whole genome

sequencing (mWGS) using StrainFacts for all samples with ≥5% total *L. crispatus* relative

abundance as determined from 16S rRNA gene sequencing. Samples were categorized based

on proportional *L. crispatus* strain abundance as >90% CTV-05 ("High CTV-05"), 10-90% CTV-

05 ("Mixed"), <10% CTV-05 ("Low CTV-05"). Strain inference was unsuccessful for a small

fraction of samples (depicted in green) due to technical failures of metagenomic sequencing.

B.   Histograms showing the number (percentage) of study participants in each treatment arm with

the indicated number of inferred native (non-CTV-05) *L. crispatus* strains detected at least once

during the trial.

C.   Metagenomically inferred *L. crispatus* strain composition throughout the trial in an example

participant from whom targeted isolations were performed at weeks 8, 12, and 24. The plot depicts

overall microbiota relative abundance, with non-*L. crispatus* species summed (gray) and inferred

*L. crispatus* strains shown individually in red (CTV-05 strain) and blue (a native strain: "Strain 14").

D.   Example *Lactobacillus* MRS agar plate from bacterial isolations showing characteristic *L.*

*crispatus* colony morphology.

E.   Genomes of *L. crispatus* isolated from the week 8, 12, and 24 visits of the participant in **Figure**

**3C** identified two strains nearly identical to the metagenomically inferred strains in these samples

(assessed by Jaccard similarity to StrainFacts-inferred genotypes) and dissimilar from all other

inferred strains in the cohort, none of which were detected in this participant's samples. The

isolated strains included the CTV-05 strain isolated from week 8 and 12 samples (red), and native

Strain 14 isolated from week 12 and 24 samples (blue; see also **Figure S3A**).

F.   Transition plot for LBP recipients showing total *L. crispatus* relative abundance (determined by

16S rRNA gene sequencing, top and bottom rows) and strain category proportions (third and

fourth rows) at each pair of consecutively scheduled post-randomization visits with available strain

inference data or at which strain inference was not performed due to <5% total *L. crispatus* relative

abundance. Strain categories in the third and fourth rows show proportions of observed *L.*

*crispatus* representing CTV-05 versus the sum of the native strain(s) at each visit; "undetermined"

refers to samples in which strain inference was not performed. Pairs including a visit in which

strain inference was unsuccessful due to technical failures of metagenomic sequencing are not

shown. For each pair of visits, the top three panels show *L. crispatus* relative abundance, visit

week, and strain category at the first visit in the pair ("Visit t") and the bottom two panels show

strain category and relative abundance at the subsequent visit ("Visit t+1"). Visit pairs are grouped

along the horizontal axis by strain category at Visit t and ordered within groups by CTV-05 strain

proportion at Visit t+1.

G. Pie charts for each Visit t strain category from **Figure 3F**, summarizing subsequent *L. crispatus*

strain category frequencies at Visit t+1.

**Figure 4: Treatment effects on mucosal inflammation and relationship to microbiota composition.**

1230

A.  Differences in log10-transformed, adjusted IL-1β concentrations between participants' pre-MTZ

visit and their ensuing post-MTZ, week 12, and week 24 visits (horizontal panels) in both treatment

arms. Each dot represents a single visit per participant.

B.  Same as **Figure 4A**. for IP-10 adjusted concentrations.

C.  Same as **Figure 4A**. and **4B** for IL-6 adjusted concentrations. Similar displays are available for

all cytokine adjusted concentrations and non-adjusted concentrations in the **SI**.

D.  DiSTATIS screeplot: eigenvalues (a.u.) of DiSTATIS compromise for the first 10 latent

components.

E.  DiSTATIS correlation circle showing the correlations between the 1st (x-axis) and 2nd (y-axis)

DiSTATIS compromise latent dimension and the microbiota topic proportions (red) or cytokine

transformed concentrations (blue).

F.  Same as **Figure 4E** for DiSTATIS 3rd and 4th latent components.

**Figure 5: Heterogeneity in intervention effects with respect to pre-MTZ microbiota**

A.  Participant-level observed outcomes for attainment of *L. crispatus*-dominance at weeks 12 and

24 (dark orange: ≥50% *L. crispatus*; light orange <50% *L. crispatus*) and BV recurrence by weeks

12 and 24 (dark blue: rBV; light blue: no rBV) for each participant with week 12 and/or week 24

data. White indicated data not available. Participants are grouped according to treatment arm

and, within treatment arm, by the most predominant bacterial genus at their pre-MTZ visit ("L."

indicates *Lactobacillus*; "BVAB1" indicates *Ca.* Lachnocurva vaginae). Predominant-genus

groupings lacking at least two participants in each treatment arm were excluded.

B. Pre-MTZ microbiota composition for each participant in **Figure 5A** (x-axis ordered and vertically

aligned as in **5A**), expressed as topic proportions (see **Figure 2A** for topic definitions).

C. Rates and associated 95% CI of *L. crispatus*-dominance (≥50% *L. crispatus*) at week 12 or 24

(horizontal panels) by pre-MTZ microbiota group in each arm. Participants are grouped based on

their most predominant genus as defined in **Figure 5A-B**. CI are computed using Wilson's scores

due to low sample sizes in some groups.

D. Rate differences (rate in LBP arm - rate in placebo arm) and associated 95% CI (Wilson's score

method) between arms for results in **Figure 5C**. Color scale shows degree of benefit (defined as

the difference in rates between the two arms) in achieving *L. crispatus*-dominance, with blue

indicating benefit with LBP treatment and red indicating benefit with placebo. *P*-values adjusted

for multiple testing (across panel **5D** and **5F**) using the Benjamini-Hochberg correction of the

analysis of deviance test for heterogeneity in treatment effects when stratifying participants

according to their most predominant genus at the pre-MTZ visit are shown in upper right corner.

E. Same as (**Figure 5C**), but for BV recurrence  by week 12 or 24.

F. Same as (**Figure 5D**), but for BV recurrence by week 12 or 24. Color scale shows degree of

benefit in reducing rBV, with blue indicating benefit with LBP treatment and red indicating benefit

with placebo.

**Figure 6: Multiblock analysis of factors associated with microbiota categories in LACTIN-V recipients.**

A. Multiblock partial least squared discriminant analysis (MB-PLS-DA, **Figure S6A**) of factors

predictive of microbiota categories (≥50% *L. crispatus*; ≥50% *Lactobacillus* and <50% *L.*

*crispatus*; or <50% *Lactobacillus*) at the indicated visits. Relative cumulative importance indices

(x-axis, Methods) are shown for each thematic block of explanatory variables (y-axis, color) for

the initial phase model (post-MTZ to Week 4; left panel), continuation phase model (Week 4 to 8

to 12; middle panel), and follow-up phase model (Week 12 to 24; right panel). Dots indicate point

estimates and translucent horizontal bars represent bootstrapped 95% CI. Vertical lines at x = 1

show the expected value under the (null) hypothesis that all variables have the same importance.

Block definitions along with the description of the variables included in each block are provided in

**Table S6**. Horizontal dashed lines separate blocks included in the nested models (**Figure S6A**,

**SI**, Methods).

B. Bi-plot for the MB-PLS-DA initial phase model (from post-MTZ to week 4). Dots represent scores

(each dot is a participant) while arrows represent loadings (each arrow is an explanatory variable,

see **Figure S7A**) for the most important variables (Methods) in the space of the 2 first latent

variables. Dots (participants) are colored by their corresponding response categories (*i.e.,* their

colonization status at week 4). Perfect separation of the categories would indicate perfect

prediction of colonization status at the week 4 visit. Arrows (explanatory variables) are colored by

the block to which they belong to - **Figure 6A** and **Table S6** serve as color legend.

C. Scree-plot of the first 15 eigenvalues of the model from **Figure 6B**. The first two latent variables

(selected by cross-validation) are shown in dark gray.

D. Transformed $\log_2$-concentrations (y-axis) of two cytokines (MIG and IL-1b) whose pre-MTZ levels

(left panel) were identified as associated with participants' colonization status at week 4 (x-axis,

colors) by the model (**Figure 6A** and **S7A**). Concentrations at the post-MTZ and week 4 visits are

shown in the middle and right panels. Each dot is a participant, colored by the colonization status

at week 4 for each panel.

**Supplementary Tables and Figures**

**Table S1**

| | At least one visit | Pre-MTZ | Post-MTZ | Week 4 | Week 8 | Week 12 | Week 24 | All planned in-person visits |
|---|---|---|---|---|---|---|---|---|
| **Total** | 211 | 208 | 203 | 181 | 172 | 179 | 165 | 139 |
| **LACTIN-V** | 142 | 140 | 138 | 124 | 120 | 123 | 113 | 99 |
| **Placebo** | 69 | 68 | 65 | 57 | 52 | 56 | 52 | 40 |

1299 Number of participants in each study arm (rows) with available 16S rRNA gene sequencing data at any,

1300 each, or all planned in-person visits (unscheduled clinic visits not shown).

1301 **Table S2**

|  | % (n) [both arm] | % (n) [LACTIN-V] | % (n) [Placebo] |
|---|---|---|---|
| ≥ 50% *L. iners* | 52 % (106) | 52 % (72) | 52 % (34) |
| ≥ 50% *L. jensenii* | 8 % (16) | 9 % (13) | 5 % (3) |
| ≥ 50% *L. crispatus* | 1 % (2) | 1 % (1) | 2 % (1) |
| ≥ 50% *Lactobacillus* (no individual species ≥ 50%) | 13 % (27) | 14 % (20) | 11 % (7) |
| < 50% *Lactobacillus* | 26 % (52) | 23 % (32) | 31 % (20) |

1302 At the post-MTZ visit, number and proportion of samples dominated by one of the top *Lactobacillus*

1303 species (top 3 rows), a mixture of *Lactobacillus* (4th row), or by non-*Lactobacillus* species in both arms

1304 (2nd column), the LACTIN-V arm (3rd column), or the placebo arm (4th column).

**Table S3**

| Microbiota outcome (16S rRNA sequencing-based) | Clinical diagnosis | |
| --- | --- | --- |
| | no rBV n (%) | rBV n (%) |
| < 50% *Lactobacillus* | 162 (50 %) | 164 (50 %) |
| ≥ 50% *Lactobacillus, <50% L. crispatus* | 192 (99 %) | 2 (1 %) |
| ≥ 50% *L. crispatus* | 209 (100 %) | 0 (0 %) |

Number of visits (n) at which participants did not (left column) or did (right column) meet diagnostic criteria for recurrent BV (rBV). Participants are shown according to microbiota category. Percentages sum to 100% for each category.

1313    **Table S4**

| Category at week 4 | Category at **week 12** | | | |
|---|---|---|---|---|
| | ≥ 50% *L. crispatus* | ≥ 50% *Lactobacillus*, < 50% *L. crispatus* | < 50% *Lactobacillus* | Total |
| ≥ 50% *L. crispatus* | 25 | 14 | 12 | 51 |
| ≥ 50% *Lactobacillus*, < 50% *L. crispatus* | 6 | 12 | 8 | 26 |
| < 50% *Lactobacillus* | 4 | 4 | 30 | 38 |
| Total | 35 | 30 | 50 | 115 |

1314    Contingency table showing the correspondence between Week 4 and Week 12 microbiota categories for

1315    LACTIN-V recipients with available data from both visits.

1316    **Table S5**

| Category at week 4 | Category at **week 24** | | | |
|---|---|---|---|---|
| | ≥ 50% *L. crispatus* | ≥ 50% *Lactobacillus*, < 50% *L. crispatus* | < 50% *Lactobacillus* | Total |
| ≥ 50% *L. crispatus* | 27 | 9 | 11 | 47 |
| ≥ 50% *Lactobacillus*, < 50% *L. crispatus* | 6 | 6 | 11 | 23 |
| < 50% *Lactobacillus* | 5 | 10 | 22 | 37 |
| Total | 38 | 25 | 44 | 107 |

1317    Contingency table showing the correspondence between Week 4 and Week 24 microbiota categories for

1318    LACTIN-V recipients with available data from both visits.

 **Table S6**

| Block | Variable | Description |
|---|---|---|
| Demographics | Age | Age of the participant at enrollment. |
| | N past BV | Number of past BV episodes (coded as a number on the following scale: (1) None, (2) 1-2, (3) Unknown, (4) 3-4, (5) 5 or more). |
| | Education level | Education level of the participant (coded as a number on the following scale: (1) Did not complete high school, (2) Completed high school, (3) Completed junior college, (4) Completed college (undergraduate degree), (5) Completed graduate degree). |
| | Race | Self-declared race of the participant (Categories with few participants were merged into "Other"). |
| Vag. env. pre-MTZ | α diversity | Shannon diversity index of baseline (pre-MTZ) microbiota, computed on taxa proportions quantified from 16S rRNA gene sequencing data. |
| | pH | Vaginal pH at the pre-MTZ visit, measured at study sites. |
| Microbiota pre-MTZ | | Pre-MTZ microbiota composition described as topic proportions. |
| Cytokine (r) pre-MTZ | | Pre-MTZ cytokine residual levels. These values are computed as the difference between the transformed cytokine/chemokines levels and their predicted value based on microbiota composition expressed as topic proportions. |
| Coloniz. cat. prev. v. | | Colonization category at the previous visit. One of these mutually exclusive categories: ≥ 50% *L. crispatus*, ≥ 50% *Lactobacillus* and < 50% *L. crispatus*, or < 50% *Lactobacillus*. |
| Vag. env. prev. v. | α diversity (r) | Difference between the Shannon diversity index at the previous visit (w.r.t the visit of the response variable), computed on taxa proportions quantified from 16S rRNA gene sequencing data, and its expected value based on colonization category at the same visit. |
| | pH (r) | Difference between vaginal pH at the previous visit, measured at study sites, and its expected value based on colonization category at the same visit. |
| | log10(bact. load) | $\log_{10}$ total bacterial load at the previous visit, quantified by qPCR. |
| Microbiota (r) prev. v. | | Difference between the observed microbiota composition at the previous visit described as topic proportions and the average microbiota composition within each colonization category. |
| Cytokines (r) prev. v. | | Cytokine residual levels at the previous visit. These values are computed as the difference between the transformed cytokine/chemokines levels and their predicted value based on microbiota composition expressed as topic proportions. |
| Birth control | Non-hormonal | A binary variable indicating whether participants reported exclusively using one of the following non-hormonal birth control methods including abstinence, use of condoms, or fertility awareness methods. |
| | IUD (Hormonal) | Same as above for hormonal intra-uterine device. |
| | IUD (Non-hormonal) | Same as above for non-hormonal intra-uterine device (copper IUD). |

| | Combined | A binary variable indicating whether participants reported using a combination of hormonal contraceptives or switched contraceptive method between the last visit and this one. |
|---|---|---|
| | P only | A binary variable indicating whether participants reported exclusively using progestin-only hormonal contraceptive, including the pill, patches, and implants. |
| | unknown | A binary variable indicating whether a participant's birth control is unknown (missing data). Each participant belongs to only one of each birth control category. |
| Sexual behavior | N new partners | Number of new sexual partners since the last visit. |
| | Any condomless sex | A binary flag indicating whether the participant reported any sexual intercourse without condoms since the last visit. |
| | Any condom sex | A binary flag indicating whether the participant reported any sexual intercourse with condoms since the last visit. |
| Perturbations | N douching | Number of days participant reported any douching episode since the last visit. |
| | N bleeding | Number of days participant reported vaginal bleeding since the last visit. |
| Antibiotics | N vag. abx | Number of days participant reported using vaginal antibiotics since the previous visit. |
| | N oral abx | Number of days participant reported taking oral antibiotics since the previous visit. |
| Adherence | N missed doses | Difference between the number of LACTIN-V doses that should have been taken between the previous visit and the current visit if the study protocol had been strictly followed and the actual number of doses that were taken. |
| | Days since last dose | Number of days since the most recent LACTIN-V dose was taken. |

1320

**Figure S1**

A.  Time-line of collected swabs from which 16S rRNA gene sequencing data could be generated.

B.  Balance between treatment arms in terms of microbiota composition at the pre-MTZ visit. The left

panel shows the top 20 eigenvalues of the PCoA (Principal Coordinate Analysis) performed on

the Bray-Curtis dissimilarity matrix, computed from the relative abundances of ASVs. The next

two panels show the PCoA scores (projection of the samples, each dot is a sample) colored by

the intervention arm for the first 4 principal coordinates. The *p*-value in the upper right corner

corresponds to the PERMANOVA test on the study arm. The right panels show the same

projections as the middle panels, but samples are here colored by topic relative abundance

(**Figure 2A-B**).

C.  Balance between treatment arms in terms of microbiota composition at the post-MTZ visit, labeled

and arranged as for **Figure S1B**.

**Figure S2**

1335

A. "Transport" alignment between topics identified by LDA models fitted on the non-*Lactobacillus*

taxa counts for varying total number of topics (K, x-axis). Each rectangle represents a topic; the

height of that rectangle represents the summed prevalence of that topic in the population, and the

size of the connection between topics is proportional to the degree of similarity between the

composition of two given topics.

B. The number of paths (y-axis) identified at each resolution (K, the number of topics considered by

the LDA models, x-axis) from the "product" alignment of topics; for details see[77]. A path identifies

a series of topics with high alignment scores throughout resolutions. A plateau in the number of

paths (here at K = 4) suggests that the 4-topic model is the model that identifies most robust

topics (i.e., topics that remain similar across resolution despite the introduction of new, potentially

spurious, topics).

C. Proportion (x-axis) of each *Lactobacillus* species (y-axis) detected across all samples. Species

with a relative abundance > 50% in at least 10 samples made up their own topic.

D. Relative abundance of taxon or topic (x-axis, colors) in each arm at each visit.

E. Microbiota stability by arm, visit, and microbiota category. Stability is quantified using the Bray-

Curtis dissimilarity, described as relative abundances at the ASV level at the participant's current

visit (vertical panels) and subsequent scheduled visit. At each visit, participants are grouped into

one of the three categories (colors, x-axis) defined earlier (*L. crispatus*-dominant, *Lactobacillus*-

dominant but low-level *L. crispatus*, and low-level *Lactobacillus*).

**Figure S3**

A. Results of targeted isolations from LACTIN-V trial samples, showing source participant, visit

number, sample *L. crispatus* relative abundance as estimated by 16S rRNA gene sequencing,

CTV-05 proportional strain abundance, and the numbers and taxonomic assignments of

genome-sequenced isolates from each sample. *L. crispatus* isolates are separated by whether

genome sequencing showed them to be CTV-05 or non-CTV-05 (native) strains. Multiple

isolates of genotypically identical strains (including of *L. crispatus* isolates) were obtained from

some samples.

B. Pie charts for each Visit t strain category from **Figure 3F** summarizing *L. crispatus* strain category

frequencies at Visit t+1, shown individually for each Visit t.

**Figure S4**

A. Distribution of unadjusted cytokine and chemokine concentrations within the dataset, with values below the lower limit of quantification (LLOQ) imputed at half the LLOQ and values above the upper limit of quantification (ULOQ) imputed at the ULOQ. Analytes were excluded from further analysis if >60% of values were below the LLOQ or >30% were above the ULOQ.

B. Pair-wise Pearson correlation coefficients between log10-transformed concentrations of each cytokine. All correlations were significant ($p < 0.05$).

C. RV coefficients (y-axis) between microbiota composition described in terms of topic proportions and cytokine/chemokine transformed concentrations at each visit (x-axis). Permutation test $p$-values were adjusted for multiple testing to control for the false discovery rate. The size of the dot is inversely proportional to the $\log_{10}$ of the associated adjusted p-value. The horizontal dashed line provides the value of the RV coefficient when computed on all visits combined.

D. IP-10 adjusted $\log_{10}$(concentrations) (y-axis) by microbiota composition categories (x-axis) at each visit (horizontal panels). Microbiota categories are mutually exclusive such that the first category (≥ 50% CTV-05) encompasses samples in which the relative abundance of CTV-05 (within the overall microbiota) is larger or equal to 50%; the second category encompasses samples with ≥50% total *L. crispatus* but <50% CTV-05 relative abundance within the microbiota; the third category includes samples in which total *L. crispatus* relative abundance is <50%, but the total *Lactobacillus* relative abundance is ≥50%, and the remaining category includes samples with <50% *Lactobacillus*. Participants from both arms are included.

E. DISTATIS screeplot from repeated DiSTATIS analysis, similar to analysis in **Figure 4D** but differentiating between CTV-05 and summed other *L. crispatus* strains. Eigenvalues (a.u.) of DISTATIS compromise for the first 10 latent components are shown.

1390       F.  DISTATIS correlation circle for the analysis in **Figure S4E**, showing the 1st and 2nd latent

1391           components (similar to **Figure 4E**).

1392       G.  DISTATIS correlation circle for the analysis in **Figure S4E**, showing the 3rd and 4th latent

1393           components (similar to **Figure 4F**).

**Figure S5**

Rates and associated 95% CI of high-level *L. crispatus* colonization (≥50% of relative abundance) (y-axis) at week 12 or 24 (left two panels, top row) or rBV by Week 12 or 24 (right two panels, top row) by pre-MTZ CST in each arm (colors), and the corresponding rate differences and 95% CI between arms (bottom row), analyzed as in **Figure 5C-F**. Analysis is restricted to CSTs with at least two participants in each arm (*i.e.,* CSTs IV-A and IV-B). The color scale in the bottom row shows the degree of benefit (defined as the difference in rates between the two arms) in achieving *L. crispatus*-dominance (left panels) or reducing rBV (right panels), with blue indicating benefit with LBP treatment and red indicating benefit with placebo. *P*-values adjusted for multiple testing using the Benjamini-Hochberg correction of the analysis of deviance test for heterogeneity in treatment effects when stratifying participants by CST

1405     at the pre-MTZ visit. The centroid definition of CST IV-A includes *Ca*. Lachnocurva vaginae (BVAB1) as

1406     a predominant taxon while CST IV-B has higher abundance of *Gardnerella* and both share moderate

1407     *Prevotella* abundance[57].

1408 **Figure S6**

1409

1410 A. Diagram depicting MB-PLS-DA nested models. To assess whether blocks contributed to

1411 explaining colonization, we compared a series of nested models (far-right labels). The full model

1412 includes all blocks and variables, while the "self-predicting" model solely includes the microbiota

1413 categories at the previous visit.

B. Number of latent component selection by cross-validation for the initial phase (left), continuation phase (middle), and follow-up phase models (S6A). Mean (dots) and 95% CI (vertical segment) of the average F1 score (y-axis) obtained when including k latent components (x-axis) on 20 random calibration (black) or validation (turquoise) set. For reference, values obtained for random permutations of the response labels are shown by the horizontal gray line and band. The number of selected latent components is shown by the light turquoise vertical band (here k = 2 for all phases).

C. Contribution of nested models for the initial, continuation, and follow-up phase models. Mean and 95%CI of the average F1 score (y-axis) on the calibration (black, "c"), validation (turquoise, "v"), or for random predictions (gray, "r") for each nested model (x-axis) including the number of latent components shown on the corresponding upper-panel.

1425    **Figure S7: Variables associated with microbiota categories in LACTIN-V recipients**

1426

A. Coefficient of association (dots, x-axis) and associated bootstrapped 95% CI (horizontal

segments) between explanatory variables (y-axis) and microbiota categories (colors, horizontal

panels, see **Figure 6A**) for each phase of the trial (horizontal panels) for MB-PLS-DA models

fitted on LBP recipient data (**Figure S6A**). Variables whose 95% CI include 0 are shown in

transparent/lighter shades. Variables are shown grouped according to their assigned thematic

blocks (**Figure 6A**, **Table S6**).

B. Self-reported education levels are significantly associated with self-reported race ($\chi^2$ *p*-value <

0.01)

C. Pre-MTZ α-diversity is higher in Black or African American participants than in White participants

(*p*-value of *t*-test on association coefficient < 0.05).

**Figure S8: Multiblock analysis of factors associated with microbiota categories in placebo recipients**

A. Number of latent component selection by cross-validation for the initial (left), continuation (middle), and follow-up phase (right) model fitted on the placebo arm data. Reads as **Figure S6B**.

B. Contribution of nested models fitted on the placebo arm data for the initial (left), continuation

(missing) and follow-up phase (right). Reads as **Figure S6C.**

C. Relative cumulative importance indices in the placebo arm (x-axis, Methods) for each block (y-

axis, color) for the initial phase model (post-MTZ to Week 4; left), continuation phase model (Week

4 to 8 to 12; middle), and follow-up phase model (Week 12 to 24; right), analogous to portrayal of

LBP arm in **Figure 6A**.

**Figure S9: Variables associated with microbiota categories in placebo recipients**

Coefficient of association (dots, x-axis) and associated bootstrapped 95% CI (horizontal segments)

between explanatory variables (y-axis) and microbiota categories (colors, horizontal panels) for each

phase of the trial (horizontal panels) when MB-PLS-DA models are fitted on the placebo arm participants'

data. Variables whose 95% CI include 0 (suggesting no statistically significant associations) are shown

in transparent/lighter shades. Variables are shown grouped according to their assigned thematic blocks

(**Figure 6A**, **S8C Table S6**).